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ABSTRACT 
 
 
Necrotizing Enterocolitis (NEC) is a disease of the neonatal gastrointestinal tract 
related to prematurity, low birth weight and formula feeding that has been linked to 
imbalances in tolerizing versus inflammatory lymphocytes.  Lipid metabolism is crucial 
to T cell phenotype.  We hypothesized that derangements in hepatic lipid processing 
predispose to inflammatory T cell types, including gamma delta T cells (GDTCs), and 
diminish tolerizing regulatory T cells (Tregs) in the genetically susceptible host. 
First, we conducted an epidemiological study of babies predisposed to NEC.  
Flow cytometric analysis was conducted on cord blood Tregs from susceptible babies.  
Next, we analyzed microarray data to determine genetic differences in lipid metabolism 
of babies who developed NEC.  We studied strain-specific differences in T cell 
activation in murine models in response to manipulations of lipid substrates.  Finally, we 
explored the direct effect of low density lipoproteins (LDL) and high density lipoproteins 
(HDL) on lymphocyte profiles in vitro and in vivo. 
We found that babies who had intrauterine growth restriction (IUGR) and were 
born to pre-eclamptic mothers had a nine-fold higher risk of developing NEC compared 
to controls.  Prematurity led to higher numbers of poorly suppressing Tregs while IUGR 
led to low frequencies of normally-functioning Tregs in cord blood.  Microarray data 
showed significant differences in cholesterol metabolism genes in babies with NEC. In 
vitro, LDL supplementation decreased Treg numbers and increased IL-17-producing 
cells (a pro-inflammatory cytokine).  Liver was found to have higher ratios of GDTCs to 
Tregs.  Finally, a neonatal mouse model of formula feeding combined with epithelial 
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destruction of the intestine showed that formula-feeding primed the immune system with 
high GDTCs and low Tregs for response to enteric pathogens, as seen in NEC. 
The implications of cholesterol metabolism in the development of NEC are novel.  
Our data suggest that lipid derangements favoring high LDL and low HDL prime the 
system towards an IL-17-producing GDTC phenotype as mediated in the liver.  These 
findings may be important for both diagnostic and therapeutic purposes, though further 
studies are needed.
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I. INTRODUCTION:  HEPATIC LIPID METABOLISM DIRECTS ENTERIC 
IMMUNITY AND DEVELOPMENT OF NECROTIZING ENTEROCOLITIS 
 
 
NEC is a disease of newborns that results in epithelial destruction of the 
gastrointestinal tract leading to a cascade of local and systemic effects.  The incidence 
is 1 in 1000 live births with a mortality of 15 - 30% and it is almost exclusively a disease 
of premature and low birth weight infants.1–4  NEC is a complex multifactorial disease, 
as risk factors from the interplay of host, microbiome, and iatrogenic events such as 
formula feeding have all been independently found to increase the risk of development 
of NEC.5,6  
Randomized trials of therapies that appear promising in animal models of NEC, 
including supplementation with lactoferrin, arginine, glutamine or probiotics, are 
incompletely characterized and therefore have not been standardized into clinical 
guidelines of care.7–10  Current practices that appear to have marginally improved NEC 
incidence and mortality over the last decade include aggressive use of breast milk, 
standardization of enteral formula feeding guidelines, delayed cord clamping, 
minimization of antibiotic use and nil per os (NPO, nothing by mouth) status.11  
However, understanding of the pathogenesis of the disease still remains limited, thus 
the quest for a unifying effective therapy remains.   
The immune response is a critical factor in the development and progression of 
the disease.  Both innate and adaptive immune mechanisms have been implicated.  
The current understanding of the disease process is that an initial breach of the 
intestinal epithelial barrier leads to a pro-inflammatory immune response and the 
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inability of the premature immune system to then counteract the inflammatory cascade 
leads to downstream effects that manifest as NEC (Figure 1).  
 
 
 
Macrophages from NEC-affected infants appear to be phenotypically different 
from healthy term neonates, expressing strongly pro-inflammatory behavior.12–14 
Depletion of neutrophils and macrophages from the intestinal lamina propria has been 
shown to exacerbate colitis in experimental NEC.15  Intraepithelial lymphocytes (IELs), 
resident lymphocytes of the gut mucosa that usually express the ϒδ T-cell receptor 
(GDTCR) and unlike classical T cells do not mount an antigen-specific response, are 
necessary for self-tolerance and habituation to commensal microbiota.16  Infants with 
Figure 1. Pathogenesis of NEC 
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NEC have been shown to have a reduction in this subset of innate-like lymphocytes, as 
well.17   
Additionally, a dysregulation in the ability to mount antigen-specific tolerance to 
both the microbiome and to self-antigens occurs in the pathogenesis of the disease.18   
Secretory IgA, required for oral and microbiome tolerance, is reduced in preterm infants.  
In experimental colitis models, decreased exposure to IgA leads to a more pro-
inflammatory gut microbiota and intestinal epithelial gene expression associated with 
inflammatory bowel disease.18  Tregs, CD4+ T lymphocytes defined by the expression 
of forkhead box P3 (Foxp3), that promote self-tolerance are also attenuated in the gut 
epithelium of infants who develop NEC.19  Pro-inflammatory cytokine expression, 
especially of IL-6 that disposes T cells to differentiate towards the pro-inflammatory T-
cell subsets (including IL-17+ cells), is also proportionately increased during 
development of NEC.20 
 One of the major foundations of immunology-based NEC research currently 
centers on the role of toll-like receptors (TLRs), transmembrane molecules that detect 
pathogen-associated ligands and affect downstream signaling to elicit an immune 
response.21 TLR4, the receptor for bacterial endotoxin that is the lipid A domain of 
lipopolysaccharide (LPS) from gram-negative bacteria, is highly expressed on fetal and 
neonatal enterocytes.  The structure of lipid A has tremendous diversity among various 
organisms.22  TLR4 appears to play a crucial role in the development of NEC.  
Premature infants have higher expression of TLR4 than full term infants due to its 
physiologic role in gut development.23  However, TLR4 activation in premature infants 
can also cause enterocyte death, loss of the epithelial barrier and bacterial 
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translocation, leading to the local and systemic effects of NEC.24  Loss or attenuation of 
TLR4 appears to have a protective effect against experimental NEC.25  
 Metabolic profiles heavily influence T cell differentiation.  Quiescent and memory 
T cells as well as Tregs use different metabolic machinery for energy and appear to be 
more dependent on oxidative phosphorylation and exogenous fatty acid utilization.26  
Conversely, effector T cells, including Th17/Th1/Th2 cells, are heavily dependent on 
upregulation of glycolytic pathways through mammalian target of rapamycin- (mTOR)-
dependent pathways.27–29  Dietary supplementation with short chain fatty acids has 
been shown to induce colonic Tregs and ameliorate experimental colitis.30–34   
The composition of dietary fat in colitis has generally been shown to have a 
profound effect on gut inflammation.  Dextran sodium sulfate (DSS), a heparin-like 
polysaccharide, that is used to induce murine inflammatory bowel disease, appears to 
exert its effects by complexing with medium chain fatty acids.35  However, in general, 
medium chain fatty acid supplementation appears to attenuate colitis.36–38  Meanwhile, 
dietary supplementation with long-chain fatty acids appear to induce gut inflammation, 
such as the polyunsaturated omega-3 docosahexanoic acid increasing FoxP3 
expression while at the same time attenuating Treg proliferation and inhibitory 
capacity.39,40   
This takes on special significance in the neonate, who switches from obtaining 
nutrients by placental transfer in utero to oral ingestion of nutrition after birth.  NEC is a 
disease almost exclusively of formula-fed infants.  Breast milk is a complex biofluid of 
which lipids are the largest source of energy, contributing 40-55% of its composition.41  
The majority of these lipids are in triacylglyceride form (TAG), with the fatty acid 
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component along the glycerol backbone being highly conserved and in specific 
positions.  Oleic, palmitic, and linoleic acids are commonly found at the sn-1, sn-2, and 
sn-3 positions.42  Lipids, including triglycerides (98%), diacylglycerides, 
monoacylglycerides, free fatty acids, phospholipids, and cholesterol, are packaged into 
a specialized carrier molecule called the milk fat globule (MFG).  The MFG is composed 
of a TAG core surrounded by a unique triple membrane structure called the MFG 
membrane.43,44 Infant formula does not contain MFG and tends to have vegetable 
source-derived lipids which differ greatly in size and composition.44,45  Supplementation 
of formula with MFG appears to protect against Clostridium dificile-induced gut 
inflammation in neonatal rat models and against gut barrier disruption and inflammation 
in systemic LPS infection.46,47 
The liver functions as the main effector organ in the processing of dietary lipids 
throughout life, as well as a primary lymphoid organ prenatally.  Fatty acids are either 
burned for energy or processed and packaged by hepatocytes into very low density 
lipoproteins (VLDL) for delivery of fatty acids and cholesterol for cellular use.  HDLs 
(“good cholesterol”) then return lipids from peripheral tissues to the liver for disposal 
through bile (Figure 2).   
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Figure 2. Lipid metabolism in the enterohepatic circulation 
Recently, oxidized LDL (“bad cholesterol”) has been demonstrated to play a role 
in IL-17-dependent inflammation in atherosclerosis.48–52 Conversely, HDL appears to 
promote a Treg-dependent reduction in inflammation.51,53  A high-fat diet has been 
demonstrated to cause Treg apoptosis in the liver without a parallel effect on splenic 
Tregs.54  Independently, infection with rhesus rotavirus, a major intestinal pathogen that 
also induces experimental biliary atresia in mouse models, has been shown to induce 
IL-17 production and concomitant decrease in anti-inflammatory IL-10 by intrahepatic T 
cells with no significant similar effect seen in mesenteric lymph nodes or gut mucosa.55  
B-cells, which present either CLIP (class II-associated invariant peptide) or antigen in 
the groove of MHC II to promote T cell activation by engagement with the T cell 
receptor, have been shown to have a high density of LDL receptors and the ability to 
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internalize LDL for processing in the lysosome, where antigen association with MHC II 
occurs as well (Figure 3).56   
Together, we therefore hypothesized that the liver plays a significant role in 
development of intestinal pathology such as NEC via crosstalk of the immune system 
and lipids and that fat content of dietary intake likely drives immune cell differentiation 
toward tolerance or inflammation (Figure 3).  
Figure 3.  Proposed mechanism 
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II. INCREASED RISK OF NECROTIZING ENTEROCOLITIS IN GROWTH-
RESTRICTED INFANTS BORN TO PRE-ECLAMPTIC MOTHERS* 
II.1 Introduction 
Maternal health during pregnancy can fate a baby to a lifetime of disease.  The 
development of pre-eclampsia (PE), a syndrome of hypertension and proteinuria that 
occurs after the 20th week of gestation in 5-8% of pregnancies in the U.S., has, in 
particular, profound and long-reaching consequences for infant health.57 Babies born to 
pre-eclamptic mothers have higher risks of perinatal complications with increased 
frequency of IUGR, immunosuppression, sepsis, and feeding problems.58–63  Endocrine, 
metabolic, nutritional and hematologic diseases continue to plague these children into 
early adulthood.64 In an era when the rising expense of medical care is increasingly at 
the forefront of debate, babies born to pre-eclamptic mothers generally have longer 
postnatal hospital courses, increased numbers of hospitalizations and higher overall 
health care costs.65  
Because PE is the basis for 15% of premature births, diseases of prematurity 
including retinopathy of prematurity, bronchopulmonary dysplasia, and NEC have all 
been associated with PE.59,66–69  However, when compared to age- and weight-matched 
controls, the presence of PE does not appear to increase the odds of  retinopathy of 
prematurity, bronchopulmonary dysplasia, and NEC or intraventricular hemorrhage and 
* Reprinted with permission from “Maternal pre-eclampsia as a risk factor for necrotizing enterocolitis” by
Lena Perger, Dhriti Mukhopadhyay, Luka Komidar, Katie Wiggins-Dohlvik, Mohammad N. Uddin & 
Madhava Beeram, 2015. The Journal of Maternal-Fetal & Neonatal Medicine, 29:13, 2098-2103, 
Copyright 2015 by Taylor & Francis. Available online: 
http://wwww.tandfonline.com/10.3109/14767058.2015.1076386. 
____________________________
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may even play a protective role in these disorders due to aggressive protocolized
prenatal treatment regimens of the mother.70–74
NEC, destruction of the gastrointestinal epithelium with invasive transmural 
bacterial infection leading to a cascade of local and systemic effects, is a highly morbid 
disease of newborns that is particularly frequent and severe in premature and growth-
restricted infants.1,4,75,76 Population-based estimates of the incidence of confirmed NEC 
in the United States are approximately 1 in 1000 live births with a mortality of 1 in 7 for 
babies hospitalized for NEC.2  Unlike other diseases of prematurity, an imbalance in the 
pro-inflammatory response has been shown to be critical to the development of NEC in 
the newborn.19  Interestingly, similar derangements in immunity underlie the 
development of PE in the mother.77 We hypothesized that maternal PE will be linked to 
the development of NEC in their newborns through the common pathophysiologic 
mechanisms at play in both mother and fetus. 
The goal for this study was twofold.  First, we compared the incidence of NEC in 
babies born to PE mothers to the incidence of NEC in babies born to non-PE mothers to 
determine if a pre-eclamptic environment was linked to the disease.  Second, we 
investigated the relative importance of PE and several infant and maternal factors when 
predicting the development of NEC.   
 
 
II.2 Patients and Methods 
 
After approval by the Institutional Review Board, the study cohort of all live births 
between January 2008 and December 2011 was retrospectively constructed using the 
Scott & White Labor and Delivery database (n=10,078).  Inclusion dates were selected 
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due to availability of an integrated neonatal intensive care unit and hospital electronic 
medical record system starting in 2008.  Exclusion criteria included non-viability of less 
than 23 weeks estimated gestational age (GA) (n=44) and inaccessible infant medical 
records (n=41) (Figure 4).   
Infant information including method of delivery, gestational age, birth weight, sex, 
and Apgar scores at 1 and 5 minutes was gathered.  Presence of IUGR was identified 
by classifying babies with birth weights less than the 10th percentile as small-for-
gestational age (SGA) in contrast to non-growth-restricted appropriate-for-gestational 
age babies (AGA).26 Babies with a diagnosis of all stages of NEC were identified using 
ICD-9 codes 777.5-777.53.  Maternal information, including age, race, and number of 
pregnancies and deliveries, was also identified and linked to baby information.  ICD-9 
code 642 for PE was used to define and separate out the study group of pre-eclamptic 
mothers.  In patients with missing individual data points, manual chart review was 
performed to complete the database.  
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Figure 4.  Inclusion criteria of PE mothers and NEC infants 
Statistical analysis was done using SPSS 20.0 software.  We used non-
parametric Mann-Whitney U and Pearson's χ2 tests to test the differences between the 
control and the pre-eclamptic group. To estimate effect size, Pearson's correlation 
coefficient (r) was used for continuous variables and Cramer's correlation coefficient 
(Cramer's V) for categorical variables.  To determine the predictive power of PE, infant, 
and maternal factors on the incidence of NEC, a hierarchical binary logistic regression 
was conducted. These three variables were entered into the model in three consecutive 
blocks. To evaluate the predictive power of PE first as a sole predictor and afterwards in 
combination with infant and maternal predictors, the presence of PE was the only 
variable entered into the first block by using the default Enter variable selection method; 
by using the Enter method, PE stayed in the model regardless of its statistical 
significance. In the case of infant (block 2) and maternal factors (block 3), the stepwise 
Forward: Likelihood Ratio method was used to retain only those predictors whose 
All births between 
January 2008 and 
December 2011 
(n=10,078)
Control (n = 8,625)
No NEC (n=8499) NEC (n-126)
Pre-eclamptic 
mothers (n = 1,368)
No NEC (n=1305) NEC (n=63)
Excluded:
-Babies < 23 weeks gestational age (n = 
44)
-Inaccessible data(n = 41)
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inclusion resulted in a statistically significant improvement of the model fit. The Wald 
statistic was used to estimate the relative importance of a certain predictor with a higher 
Wald statistic translating to higher relative importance.  
  
II.3 Results 
 
First, we characterized the population of infants and mothers analyzed in this 
study according to significant demographic and clinical factors.  Overall infant 
demographics showed a predominance of babies of Caucasian descent of equal gender 
distribution born at term with normal birth weight, modeling the semi-rural population 
served by our institution.  Clinical status at birth, reflected by Apgar scores at 1 and 5 
minutes, were similar between the two groups.  However, detailed analysis showed that 
the pre-eclamptic group had moderately higher percentages of African-American 
babies, pre-term births and low-birth weight and growth-restricted infants (Table 1).   
Pre-eclamptic mothers were slightly older than control mothers.  Both groups had 
a median of two pregnancies with one birth at the time of gestation of the study 
population.  Multiple gestations and delivery by cesarean section were more prevalent 
in pre-eclamptic mothers compared to the general population (Table 1). 
In the next step, we carried out a hierarchical binary logistic regression to predict 
NEC by PE, infant, and maternal factors (Table 2). When PE was entered as a sole 
predictor, it proved to be a statistically significant predictor of NEC; infants born to pre-
eclamptic mothers had approximately 3.3 times higher odds of developing NEC. 
However, when we added the infant factors in the second step, the effect of PE became 
non-significant, most likely due to the large effects of infant weight and age. It is 
important to note that the large effects of weight and age also resulted in the exclusion 
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of gestational size in the model. Adding the third block predictors revealed that maternal 
age, multiple gestation, and delivery method also significantly contribute to the 
development of NEC.  
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Table 1. Infant and maternal demographics 
 
INFANT CHARACTERISTICS Control  
(n=8625) 
Pre-eclamptic 
(n=1368) 
p-value Effect size* 
Gender (% female) 4229 (49.0) 677 (49.5) 0.75 Cramer’s V<0.01 
Race   <0.001 Cramer’s V=0.08 
White 4229 (49.0) 674 (49.3)   
Black 1233 (14.3) 293 (21.4)   
Hispanic 1980 (23.0) 265 (19.4)   
Asian  143 (1.7) 16 (1.2)   
Other  919 (10.7) 103 (7.5)   
Birth weight (g) – median 
(IQR) 
3293 (2920-
3617) 
2938 (2287-
3394) 
<0.001 r=0.18 
Birth weight groups (%)    <0.001 Cramer’s V=0.21 
Normal (>2500 g) 7693 (89.2) 943 (68.9)   
Low (1500–2500 g) 683 (7.9) 280 (20.5)   
Very Low (1000–
1500 g) 
111 (1.3) 71 (5.2)   
Extremely Low 
(<1000) 
138 (1.6) 74 (5.4)   
Presence of Intrauterine 
Growth Restriction (% 
SGA) 
542 (6.3) 140 (10.2) <0.001 Cramer’s V=0.05 
Gestational Age (wks) – 
median (IQR) 
39.1 (37.9-39.9) 37.2 (35.0-38.9) <0.001 r=0.25 
Preterm births (%) 1248 (14.5) 566 (41.4) <0.001 Cramer’s V=0.24 
Apgar at 1 minute – 
median (IQR) 
8.4 (7.6-9.0) 8.0 (6.8-8.8) <0.001 r=0.13 
Apgar at 5 minutes – 
median (IQR) 
8.9 (8.4-9.5) 8.8 (8.2-9.4) <0.001 r=0.14 
Cases of necrotizing 
enterocolitis (%) 
126 (1.5) 63 (4.6) <0.001 Cramer’s V=0.08 
MATERNAL 
CHARACTERISTICS 
Control (n=8471) Pre-eclamptic 
(n=1308) 
P-value Effect Size 
Mean age (SD) 25.6 (5.6) 26.8 (6.1) <0.001 r=0.07 
Gravidity – median (IQR) 2.2 (1.3-3.4) 2.0 (1.2-3.5) 0.14 r=0.01 
Parity – median (IQR) 0.7 (0.1-1.7) 0.6 (0.0-0.5) <0.001 r=0.04 
Number (%) single 
gestations 
8323 (98.3) 1252 (95.7) <0.001 Cramer’s V=0.09 
Number (%) delivered 
vaginally  
6396 (74.2) 787 (57.6) <0.001 Cramer’s V=0.13 
*Interpretation of effect size: Small (0.10-0.30), Medium (0.30-0.50), Large (>0.50) 
IQR – interquartile range 
SGA – small for gestational age 
SD – standard deviation 
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Table 2. Predictors of NEC development 
 
Predictor# R2 Model  (df) Wald 
Odds 
ratio 95% CI for OR 
Block 1 .028 38.44 (1)***    
Constant   1775.31 0.01  
Pre-eclampsia   44.90 3.27*** 2.31–4.62 
Block 2a .448 633.76 (4)***    
Constant   10.14 50.91  
Pre-eclampsia 
(present)   0.35 1.14 0.75–1.73 
Infant age (weeks)   5.81 0.88* 0.79–0.98 
Infant weight (100 
g)   16.36 0.88*** 0.83–0.94 
Gestational status   6.23 2.56* 1.23-5.55 
Block 3b .463 656.56 (7)***    
Constant   9.49 70.51  
Pre-eclampsia   0.01 1.03 0.66–1.59 
Infant age (weeks)   7.55 0.86** 0.77–0.96 
Infant weight (100 
g)   13.34 0.89*** 0.84–0.95 
Gestational status   6.73 2.7** 1.28-5.88 
Mother's age 
(years)   4.44 0.97* 0.93–0.99 
Multiple gestation   7.02 2.16** 1.22–3.82 
Delivery method   13.64 2.17*** 1.44–3.27 
#All dichotomous categorical predictors were coded with 0 and 1; the value of 0 indicates the reference value for 
interpreting the corresponding odds ratio. The reference values were set as follows: PE (absence of PE), gestational 
status (term), multiple gestation (single), and delivery method (vaginal). 
aExcluded predictors: Gestational size, Apgar 1, Apgar 5, Infant gender, Infant race. 
bExcluded predictors: Gestational size, Apgar 1, Apgar 5, Infant gender, Infant race, Gravidity, Parity. 
*p<0.05, **p<0.01, ***p<0.001 
 
 
In sum, we found three infant and three maternal factors that significantly 
contribute to development of NEC independently if all other measured variables are 
controlled. For every one week increase in age and every hundred grams increase in 
weight, the odds of developing NEC decrease by a factor of 0.86 and 0.89, respectively. 
Babies who were pre-term had a 2.7 (i.e. 1/0.37) times higher odds of NEC than term 
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babies, babies who were a product of multiple gestation had a 2.16 higher odd of NEC 
than singletons, and babies delivered by C-section had a 2.17 times higher odd of 
developing NEC than vaginally delivered babies. 
Although PE did not turn out to be a significant predictor of NEC when controlling 
for infant and maternal factors, we suspected an effect hidden in interactions with the 
most important predictors. Therefore, we conducted additional analyses in terms of 
incidence and relative risks (RR) of developing NEC in the presence of PE compared to 
non-PE controls (Figure 5A-D). This was done separately for groups defined by 
gestational size, gestational status, multiple gestation, and delivery method and then 
RRs for each group calculated as a ratio of the incidence of NEC in the PE group (% of 
NEC infants with PE mothers) to the non-PE group (% of NEC infants with non-PE 
mothers).  These additional analyses revealed important interactions of PE with 
gestational size, multiple gestation, and method of delivery when predicting the 
incidence and risk of developing NEC.  
           In the case of AGA babies, PE had a rather small effect, for babies born to 
PE mothers were only 2.5 times (p<0.01) more likely to develop NEC (Figure 
5A).  Within the cohort of SGA babies, the incidence of NEC in non-PE babies 
was 1.5%, similar to the population incidence.  However, this was dramatically 
different from the PE group, which had an incidence of 13.6% (p<0.001). SGA 
babies born to pre-eclamptic mothers were therefore 9.2 times more likely to 
develop NEC than SGA babies born to non-PE mothers (p<0.001).  
Term babies had an incidence of 0.18% of NEC in non-PE and 0.25% in 
PE babies.  Within the preterm population, 9.0% of control babies and 10.8% of 
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PE babies developed NEC (p=0.25).  Pre-term birth clearly represents a risk 
factor for developing NEC (Figure 5B). However, the RRs revealed that PE did 
not appear to play an important role in term or pre-term babies, because ratios 
were quite small and did not significantly differ from 1.00 (P>0.05).  
Other significant factors found were that babies who were the product of a 
multiple gestation were more likely to develop NEC than single born babies 
(Figure 5C). Interestingly, the presence of PE was associated with an increased 
risk of NEC in singletons, yet not in multiple gestations; multiple gestation babies 
born to PE mothers were only 1.1 times (P>0.05) more likely to develop NEC, 
whereas single born babies born to PE mothers were 3.5 times (P<0.001) more 
likely to develop NEC than those born to non-PE mothers.  Additionally, babies 
delivered by C-section who were born to PE mothers were 3.1 times (P<0.01) 
more likely to develop NEC than their non-PE counterparts (Figure 5D). In the 
case of vaginally delivered babies, however, PE did not significantly increase the 
risk of developing NEC. 
 
 
 
 
 
Figure 5. Incidence of NEC. Data is stratified by presence of PE and infant (gestational size and 
status) and maternal (multiple gestation, method of delivery) factors. Relative risks in the right 
column were calculated as a ratio between incidence of NEC in the pre-eclampsia group (PE) 
and incidence of NEC in the non-PE group. All whiskers represent 95% confidence intervals for 
incidence of NEC (left column graphs) and for relative risks (right column graphs). AGA = 
appropriate for gestational age birth weight > 10th percentile; SGA = small for gestational age < 
10th percentile; C/S = cesarean section; VAG = spontaneous vaginal delivery. 
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A - Gestational size 
 
 
 
 
 
B - Gestational status 
 
 
 
 
C - Multiple gestation 
 
 
 
 
 
 
D - Method of delivery 
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II.4 Summary 
 
We have shown that, overall, a baby born in a pre-eclamptic environment has a 
threefold increase in the odds of developing NEC.  Though the power of maternal PE in 
predicting infant NEC is dampened by the much stronger and already well-characterized 
infant characteristics of low birth weight and prematurity, our subgroup analyses show 
dramatic associations that have never been described previously.  In the subset of 
babies who are born SGA, a comparative birth weight measure that signifies intrauterine 
growth restriction, a pre-eclamptic intrauterine environment imparts a nine-fold higher 
risk ratio of NEC development than similar babies born to non-pre-eclamptic mothers.  
Interestingly, a similar pattern is not found in premature infants; babies born early 
secondary to PE have no significant increased risk of NEC compared to those born pre-
term for other causes. 
Importantly, other maternal characteristics including multiple gestation and mode 
of delivery have significant associations with the development of NEC as well, which 
have not been previously described or examined in the literature.  After controlling for 
the infant factors, we found a 2.16 higher odds of NEC in babies who were a product of 
multiple gestation and 2.17 higher odds of babies delivered by cesarean section.  
Because this study was not designed to investigate these associations, further research 
is needed to explore these findings. 
As with any retrospective database review, there are two significant weaknesses 
in this study.  First, because data was not collected prospectively, findings suggest 
associations but not causality.  Second, though some of the inherent drawbacks of 
database review were mitigated by manual correction, data collected by mining for ICD 
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(International Classification of Diseases) codes is only as strong as the accuracy with 
which codes were entered in the first place.  Additionally, because this is a single center 
study in a semi-rural setting, there may be a component of selection bias with some of 
the associations being population-dependent and not translatable to the general 
population. 
Our study had an incidence of Bell’s stage II and III NEC (39/9993 ≈ 4/1000 live 
births) similar to previously reported population-based findings.1  Other strengths of the 
study are that our results do accurately model the disease and patient characteristics of 
our stable semi-rural patient population due to the cohesiveness of our hospital system. 
Unlike other population-based studies, our study captures all patients who were 
suspected to have developed NEC, thereby properly capturing babies with NEC 
responsive to medical treatment without overt radiographic signs (Bell’s Stage I).  
Finally, because of the comprehensiveness of our integrated electronic medical record, 
we were able to manually correct missing or aberrant data in a manner that most other 
retrospective database studies cannot. 
PE and NEC are complex heterogeneous disease states and their etiologies are 
incompletely understood.  However, our hypothesis stems from and our results can in 
part be explained by a shared pathophysiology driven by the placenta that leads to a 
poorly regulated pro-inflammatory state in both processes.  
The current paradigm is that the underlying vascular insufficiency of the placenta 
drives both PE and NEC.  In PE, multifactorial aberrations in the normal mechanisms of 
pregnancy initiation and maintenance lead to its development in two stages. First, early 
in pregnancy, aberrant spiral artery remodeling by the cytotrophoblast leads to poor 
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placental blood supply.  Poor perfusion precipitates an inflammatory response by the 
placenta, which, in the susceptible host leads to the second stage, a systemic response 
that manifests in the classic findings of PE.62,78  Current research supports that placental 
hypoxia causes an upregulation of the transcription factor hypoxia-inducible factor 1α 
(HIF-1α) in maternal circulation.77,79,80  HIF-1α is critical for tipping the balance of 
differentiation of naïve CD4+ TH cells toward a pro-inflammatory TH17 phenotype over 
the anti-inflammatory regulatory T cell (Treg) phenotype.81  PE has been shown to have 
a TH17–predominant CD4+ T cell lymphocyte pool compared to the significant Treg 
expansion found in normal pregnancy.77,82–84,84–86 
The placenta, which serves as the sole source of oxygen and nutrient delivery to 
the infant, is a critical organ for fetal growth and development.87,88  Abnormalities in 
placental development, necessary for PE, also underlie pathologic IUGR.26 Just as in 
the maternal circulation, placental hypoxia causes HIF-1α up-regulation, and similar 
processes likely occur in utero during fetal development.  In fact, babies who develop 
necrotizing enterocolitis have been found to have a relative dearth of intestinal 
Tregs.19,89  SGA infants have also been shown to have lower proportions of circulating 
Tregs immediately at birth prior to encounter of foreign antigen.90  This suggests that 
babies who are exposed to intrauterine hypoxia, manifested as growth restriction, are 
immunologically primed to mount a pro-inflammatory response due to the same 
transcriptional changes that have been found in the mother.  
A different paradigm may be that the underlying aberration is instead secondary 
to altered lipid metabolism driven by the fetus rather than vascular insufficiency and 
hypoxia.  PE is known to lead to increased cardiovascular risk later in life, though the 
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cause for this remains unknown.  Multiple studies have shown measurable alterations in 
serum fatty acid binding proteins, specifically fatty acid binding protein 4, in women with 
PE, though levels are not predictive of severity of PE.91–93  However, severe PE, which 
manifests as the HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), 
and other pregnancy-related liver disease, including acute fatty liver of pregnancy, 
appear to be related to a defect in fetal fatty-acid oxidation secondary to a deficiency in 
long-chain 3-hydroxyacyl-coenzyme A (CoA) dehydrogenase, a portion of the 
mitochondrial trifunctional protein necessary for fatty acid beta-oxidation.94–96  
Furthermore, placental proteins are encoded by the fetal genome, and genetic 
polymorphisms in lipoprotein metabolism of the fetus have been shown to influence 
maternal lipid profiles during pregnancy independent of maternal genetics.97  Women 
with PE have been found to have lower HDL levels and more atherogenic LDL 
particles.98  Severe early-onset PE (before 20 weeks’ gestation) has been linked to 
hypertriglyceridemic dyslipidemia and significantly lower levels of ApoB-100.99  
Underlying defects in fetal lipid metabolism that drive modification of maternal lipid 
profiles by the placenta not only explain the disproportionate increase in IUGR 
secondary to PE, but also the increased risk of maternal cardiovascular disease later in 
life despite no differences in lipid profiles or hypertension after delivery. 
We postulate a two-hit model in which babies who develop IUGR are born 
immunologically primed to respond with an overwhelmingly pro-inflammatory phenotype 
due to genetic polymorphisms in lipid metabolism, and require a second hit from the 
external environment that allows the development of NEC.  Further clinical and basic 
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studies are needed to elucidate the prenatal interventions that may modify these risks 
and provide targets for future diagnosis and therapy. 
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III. INTRAUTERINE GROWTH RESTRICTION AND PREMATURITY
INFLUENCE REGULATORY T CELL DEVELOPMENT IN NEWBORNS** 
III.1 Introduction 
The immune system is a complex network of cellular and humoral checks and 
balances.  CD4+ regulatory T cells (Tregs), characterized by the simultaneous 
expression of an IL-2 receptor α-chain (CD25) and transcription factor forkhead box P3 
(FoxP3), are a potent segment of the negative regulatory arm of immune system in their 
physiologic role in suppressing adaptive immune responses.100,101 Their importance as 
effectors of self-tolerance and regulators of overzealous immune activation to foreign 
antigen is well characterized for primary diseases of immunity such as autoimmunity 
and allergy.102,103 Yet, much remains unknown about their diverse role in a variety of 
physiologic and pathologic situations.   
Specifically, Tregs have been implicated in the development of NEC.104  
However, baseline values of circulating Tregs in infants at birth have not been 
established.  Their dynamics in the early post-natal period and in newborn health and 
disease remain to be characterized.  Tregs are currently defined as 
CD3+/CD4+/FoxP3high/CD25high cells by flow cytometry, a method of analysis that 
enables precise counting of blood cells using intra- and extracellular markers.  The first 
objective of this study, therefore, was to establish normal values of Treg frequency and 
activity in cord blood of healthy newborns using contemporary criteria.  
** Reprinted with permission from “Intrauterine growth restriction and prematurity influence regulatory T 
cell development in newbors” by Dhriti Mukhopadhyay, Laura Weaver, Richard Tobin, Stephanie 
Henderson, Madhava Beeram, Martha Karen Newell-Rogers and Lena Perger, 2014. The Journal of 
Pediatric Surgery, 49:5, 727-32, Copyright 2013 by Elsevier.  
____________________________
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Local and systemic injury in NEC is mediated by an overwhelming pro-
inflammatory response of the immune system.  Lack of suppression of this response 
may be attributed to decreased numbers or activity of Tregs.  Previous studies utilizing 
flow cytometric analysis of Tregs suggest that numbers of CD25+/CD4+ T cells and 
expression of FoxP3 are both inversely correlated with gestational age.104  FoxP3 
expression also appears to be attenuated in SGA infants compared to age-matched 
controls.105  Because NEC disproportionately affects babies who are born prematurely 
or with IUGR in frequency and severity, our secondary objective was to determine 
whether such incomplete or restricted development during the fetal period translated to 
decreases in Treg populations or activity prior to development of disease.106 
 
III.2 Methods/Materials 
Selection of Subjects 
A prospective study was conducted between June 2012 and January 2013 with 
IRB approval (protocol 710737).  All live births were included in the study with the 
exception of babies born to mothers with active infection or transfers from outside 
hospitals due to cord blood unavailability.   Historical data was not available to power 
the study but a projected sample size of ten per study group was determined through 
feasibility analysis.  The study was closed once this sample size was achieved in each 
group. 
Patients were assigned by gestational age and birth weight according to standard 
AAFP growth curves into the following groups:107 
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1. Term (>37 weeks) and appropriate for gestational age (AGA > 10th percentile 
on the growth curve),  
2. Term and small for gestational age (SGA ≤ 10th percentile),  
3. Pre-term (<37 weeks EGA) AGA  
a. Late (born between 33-36 weeks), 
b. Early (born between 23-32 weeks), 
4. Pre-term SGA. 
 
Samples 
Cord blood routinely collected in EDTA-coated vacutainers (BD, Franklin Lakes, 
NJ) following birth was obtained from the institutional blood bank within three days of 
birth.  Two hundred and ten total samples were collected and processed until all study 
groups were filled.   Two to three mL of blood per patient was processed to isolate cord 
blood mononuclear cells (CBMCs) using cellular density gradient centrifugation 
according to the manufacturer’s instructions (Lymphoprep, Accurate Chemicals, 
Westbury, NY).  Samples processed not according to protocol or with technical issues 
were excluded from analysis. 
 
Flow Cytometry 
Isolated CBMCs were stained for cell-surface markers using fluorescence-
conjugated primary mouse anti-human antibodies, anti-CD3 (Pacific Blue), anti-CD4 
(PE-Cy7), and anti-CD25 (APC) as well as intracellular anti-FoxP3 (PE) (all antibodies 
from BD Biosciences, San Jose, CA), with a PE-anti-mouse/rat FoxP3 staining set (e-
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Biosciences, San Diego, CA).  Cells were analyzed using flow cytometry (BD FACS 
Canto II Flow Cytometer, Franklin Lakes, NJ).  
 
Statistical Analysis   
Samples were analyzed by comparison to isotype controls.  Using standard 
gating for all samples, we determined CD4+ T cell numbers (defined as CD3+, CD4+) 
and within this population, Tregs were counted (defined as CD25high, FoxP3high).  Due 
to significant variability in number of cells per sample, final analyses were performed by 
determining cell ratios rather than absolute numbers.  Flow cytometry data was used to 
calculate the percentage of CD4+ T-cells of all CBMCs and the percentage of Tregs of 
all CD4+ T-cells. Mean fluorescence intensity (MFI) was calculated as geometric mean 
of FoxP3 in CD4+ T-cell populations per sample (FlowJo 10.0.0 software), which 
measures the expression of FoxP3 and has been validated in the literature as 
proportionate to Treg suppressive ability.101  In order to normalize suppressive ability, 
we defined an index for the comparison of MFI per Treg  (total FoxP3 MFI/absolute 
number of Treg) as the suppressive index (SI) of each sample to determine suppressive 
capability of individual Tregs in each patient.  
GraphPad Prism 6.0c software was utilized for statistical analysis using Mann 
Whitney test, Kruskall-Wallis and linear regression in order to compare groups with non-
parametric distributions.  Significance was defined as p<0.05. 
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III.3 Results 
Demographics 
Study populations were similar to the control group in terms of gender and ethnic 
distributions as well as method of birth (Table 3).  Median Apgar scores at 1 and 5 
minutes were significantly lower with younger gestational age (9/9 in term infants, 8/9 in 
late pre-term and 7/7 in early pre-term).  SGA babies were significantly more often born 
to nulliparous women than AGA babies, regardless of gestational age (nulliparous: 28% 
controls, 33% late pre-term, 38% early pre-term vs. 50% term SGA, 80% pre-term 
SGA). 
 
 
Table 3. Characteristics of study population 
 
 TERM  PRE-TERM   
 Term AGA 
n=80 
Term SGA 
n=18 
Late Pre-term 
AGA (33-36 
weeks) 
n=33 
Early Pre-
term AGA 
(23-32 
weeks) 
n=13 
Pre-term 
SGA 
n=10 
Gestational Age 39.2 ± 1.0 38.9 ± 1.2 35.3 ± 1.0 28.9 ± 2.4 32.0 ± 3.7 
Birth Weight 3452 ± 401 2495 ± 284 2576 ± 440 1278 ± 512 1388 ± 485 
Gender (%male) 41% 44% 61% 62% 40% 
Mode of Delivery 
(%SVD) 
46% 56% 45% 85% 60% 
Ethnicity      
% Black 15% 28% 21% 23% 10% 
% White 50% 39% 52% 62% 60% 
% Hispanic 28% 17% 9% 15% 20% 
Apgar at 1 minute 8.5 ± 0.7 8.3 ± 1.5 7.7 ± 1.8 6.2 ± 2.0 8.3 ± 0.9 
Apgar at 5 minutes 9.1 ± 0.3 9.0 ± 0.5 8.7 ± 1.0 6.7 ± 1.6 8.9 ± 0.4 
Maternal gravidity 
(% primagravida) 
21% 50% 33% 31% 80% 
Maternal parity 
(%nulliparous) 
28% 50% 33% 38% 80% 
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Mode of Delivery 
Comparisons of babies born by uncomplicated spontaneous vaginal delivery 
(SVD) and elective Cesarean section (C-section) were conducted in the term AGA 
group.  No significant differences were found in CD4+ T-lymphocyte or Treg 
percentage, MFI or SI between the two groups.  The mode of delivery did not appear to 
have a significant immediate effect on regulatory T-cell populations or activity in 
newborn peripheral blood, so babies born by both methods were included as the control 
group for all subsequent analyses (Table 4). 
 
 
Table 4. Effect of mode of delivery 
 
 
Spontaneous 
Vaginal Delivery 
(n=40) 
Cesarean Section 
(n=29) p-value 
%CD4 T cells of total 
cells counted 
13 ± 11 10 ± 6 0.9542 
% Treg of CD4+ T 
cells 
7 ± 4 9 ± 6 0.1166 
Treg mean 
fluorescence 
intensity 
4603 ± 3165 4011 ± 2147 0.2177 
Treg suppressive 
index 
177 ± 272 127 ± 272 0.9398 
 
 
Intrauterine Growth Restriction 
Term appropriate-for-gestational-age babies (AGA, n=80) were compared to term 
small-for-gestational-age babies (SGA, less than 10th percentile birth weight, n=18) to 
determine the relationship between IUGR and regulatory T cells.  Results are 
summarized in Figure 6.  Median Treg percentage of CD4+ T cells was found to be 
significantly lower in the SGA group (7% in AGA vs. 6% in SGA, p=0.0121). The SGA 
group also had FoxP3 MFI that was significantly lower than in AGA babies (3602 in 
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AGA vs. 2686 in SGA, p=0.0021).  However, when the Treg suppressive index of the 
two groups was compared (67 in AGA vs. 81 in SGA, p=0.6905), no significant 
difference was found.  Together, this suggests a significant decrease in normally 
functioning Tregs secondary to IUGR.  These differences, though seemingly small, are 
likely clinically relevant due to the small number of Tregs necessary in the circulation for 
function. 
 
Gestational Age 
AGA babies born at 37 weeks estimated gestational age (EGA) or later (term, 
n=80) were compared to AGA babies born between 33 and 36 weeks EGA (late pre-
term, n=33) as well as between 23 and 32 weeks EGA (early pre-term, n=13) to 
investigate the changes in Tregs through gestation.  Results are summarized in Table 5 
and Figure 6. A significant decline in median CD4+T cell percentages was observed 
early in the third trimester, between the early pre-term and late pre-term groups (16% in 
early vs. 12% in late pre-term, p=0.0218), then remained steady through the completion 
of gestation (10% in the term group).  Treg numbers also declined through gestation, 
but this occurred later in the third trimester, upon completion of gestation.  Early pre-
term and late pre-term groups had no significant difference in Treg percentages (10% in 
early and 11% in late) but there was a significant decline in babies who were born at 	
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A.	
B.  
C.  
 
Figure 6. CD4+ and Treg population characteristics according to birth weight in term infants.  A. 
Representative samples of flow cytometric analysis of term appropriate for gestational age infant showing 
all cells gated in first panel, CD3+/CD4+ cells gated in second panel representing CD4+ T cells and 
FoxP3high/CD25high cells gated in third panel representing Tregs.  B. Flow cytometric analysis for term 
small for gestational age infant.  C.  Appropriate for gestational age (AGA) are compared to small for 
gestational age (SGA) infants with median and interquartile range denoted by long and short horizontal 
bars, respectively. Significance defined as p<0.05 marked with an asterisk*. 
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Table 5. Changes in CD4+ and Treg populations through gestation 
 
 
Early Pre-
term (23 – 
32 weeks) 
n = 13 
Late Pre-term 
(33 – 36 
weeks) 
n = 33 
Term 
(37+ weeks) 
n = 80 p-value 
%CD4 T cells of total 
cells counted 
20 ± 11 12 ± 8 12 ± 9 0.0218 
% Treg of CD4+ T cells 10 ± 4 11 ± 6 8 ± 5 0.0025 
Treg mean fluorescence 
intensity 
4720 ± 1753 4879 ± 2878 5054 ± 6586 0.4332 
Treg suppressive index 56 ± 72 76 ± 110 173 ± 285 0.0037 
 
 
 
 
 
Figure 7.  Treg characteristics through gestation.  A. Representative samples of flow cytometric analysis 
of term appropriate for gestational age infant showing all cells gated in first panel, CD3+/CD4+ cells gated 
in second panel representing CD4+ T cells and FoxP3high/CD25high cells gated in third panel 
representing Tregs.  B. Flow cytometry for late pre-term appropriate for gestational age infant (33 – 36 
weeks). C. Flow cytometry for early pre-term appropriate for gestational age (23 – 32 weeks).  D.  Linear 
regression shows a gradual decrease in Treg proportions from 23 weeks gestational age until term (r = -
0.222). E. Concurrently, there is an increase in the Treg suppressive index (r = 0.119). 
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Though MFI remained steady throughout gestation (4720±1753 in early pre-term, 
4879±2878 in late pre-term, and 5054±6586 in term, p=0.4332), suppressive index rose 
steadily through gestation, which was statistically significant (56±72 in early pre-term vs. 
76±110 in late pre-term vs. 173±285 in term, p=0.0037), as shown in Figures 7 and 8.  
This data may suggest attenuation of Treg numbers due to clonal selection of more 
powerfully suppressive Treg subsets through fetal maturation.  
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a. Treg percentage through gestation 
 
 
b. Treg mean fluorescence intensity through gestation 
 
 
c. Treg suppressive index through gestation 
 
Figure 8. Decline in Tregs through maturation with accompanying increase in MFI and SI. 
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III.4 Summary 
The interplay of intrinsic and environmental factors in a developing infant is so 
complex that no single insult has yet been identified that reproducibly leads to the 
development of NEC.  Infant characteristics such as prematurity and growth restriction, 
as well as environmental factors like microbial colonization and formula feeding have all 
been implicated as risk factors.  It is clear from the extensive body of literature that a 
multitude of derangements at any point during uterine life can predispose a baby to this 
potentially devastating disease.108–111  The stage for its development is likely set 
prenatally in a genetically susceptible infant who then sustains a postnatal 
environmental insult.  Bacterial translocation through damaged epithelium combined 
with a pro-inflammatory immune state leads to intestinal necrosis, systemic sepsis and 
the short- and long-term manifestations of NEC.106   An overwhelming systemic and local 
immune response is an important etiologic factor in its pathogenesis and the role of 
Tregs as powerful regulators of the immune system needs to be defined in order to 
target them as a potential prophylactic or therapeutic option in NEC.112–114  
 This study thus establishes how Tregs, a preventive arm of adaptive immunity, 
are affected by the two most well-characterized risk factors for NEC, growth restriction 
and prematurity, immediately at birth prior to environmental influences.107,111,115   Tregs 
have been shown to be critical for protection against intestinal ischemic and 
inflammatory injury.27,116  IUGR is associated with placental insufficiency and fetal 
hypoxia, which likely lead to hypoxic conditions shown to affect the development of Treg 
populations.19,117,118   Given that epithelial ischemia is part of the cascade that ultimately 
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leads to NEC, a decrease in numbers or function of Tregs not only locally but 
systemically may be a contributing factor.  
Previous studies have demonstrated a decreased ratio of Tregs to effector CD4+ 
cells locally in the intestinal tissue of premature newborns with NEC.104  Systemically, it 
has been suggested that Foxp3 expression decreases with decreasing birth weight and 
increasing gestational age.101,119  Our study further qualified previous findings by 
definition of the Treg suppressive index.  Using this measurement, we showed that 
despite decreased percentages of circulating Tregs in the cord blood, growth-restricted 
babies actually had intact individual Foxp3 expression.  This suggests that an 
intrauterine insult that results in growth-restriction may also result in an immune 
phenotype skewed towards a pro-inflammatory state; Tregs therefore remain functional 
but are fewer in number.  In contrast, premature babies showed an increased 
percentage of Tregs in their CD4+ T-cell population, resulting in the appearance of 
intact Foxp3 expression.  However, suppressive indices were lower in younger infants 
and actually increased through gestation, suggesting a physiologic clonal deletion of 
less functional Tregs through gestation, preparing the infant for interaction with the 
external environment.  Through these different mechanisms, Treg numbers or function 
may play a role in the multifactorial etiology of NEC.   
 Establishment of normal baseline values of Tregs in human babies and how they 
are quantitatively and qualitatively affected by prematurity and growth restriction lays 
the groundwork for future research in diseases of premature and IUGR infants, 
especially necrotizing enterocolitis.  Linking the findings of Treg populations and 
dynamics in peripheral blood and how they change in the subset of babies who go on to 
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develop NEC has exciting implications for risk-stratification, diagnosis and even therapy.  
Regulatory T cells remain an exciting branch of immunology research, but much 
remains to be discovered with respect to their role in diseases of prematurity and how 
they are influenced by the combination of baby, mother and environment.  
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IV. LIPID METABOLISM INFLUENCES TREG PROLIFERATION 
 
IV.1 Introduction 
In recent years, the field of immunometabolism has begun to explore the 
importance of metabolic strategy and metabolic byproducts on immune profiles.  Within 
the CD4+ T cell compartment, quiescent and memory T cells and anti-inflammatory 
Tregs appear to utilize different substrates for mitochondrial functions compared to 
rapidly proliferating, pro-inflammatory conventional T cells (Tcons), which include IL-17-
producing Th17 cells, Th1 and Th2 cells.  This difference rests keenly on the dichotomy 
between fat and glucose metabolism.27,120–123  Memory cells and Tregs appear more 
dependent on oxidative phosphorylation and exogenous lipid utilization, including fatty 
acids (FA).26,124,125  Meanwhile, Tcons also utilize oxidative phosphorylation but are 
primarily dependent on upregulation of glycolytic pathways through mammalian target of 
rapamycin (mTOR)-dependent pathways.27–29   
  Nutrient availability and composition therefore have a significant impact on 
immune profile and disease progression as well.  Examination of the effect of various 
lipid components on gut mucosal immunity has provided key insights into this process.  
Dietary supplementation with short chain FA induces colonic Tregs and ameliorates 
experimental colitis.30–34  Medium chain FA supplementation appears to attenuate 
colitis.36–38  Meanwhile, dietary supplementation with long-chain FA appear to induce 
gut inflammation, including treatment with the polyunsaturated omega-3 
docosahexanoic acid that increases FoxP3 expression while at the same time 
attenuating Treg proliferation and inhibitory capacity.39,40  Ma et al. have shown that a 
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high-fat diet leads to Treg apoptosis in the liver without a demonstrable effect on splenic 
Tregs.54   
Systemically, lipid trafficking largely occurs via complex lipoprotein particles that 
consist of triglycerides, cholesterols, and surface apolipoproteins.  These include 
chylomicrons that transport from the gut to the liver, VLDL, intermediate-density 
lipoprotein (IDL), and LDL that delivers triglycerides and cholesterol to extrahepatic 
tissues, and HDL that traffics cholesterol back to the liver for excretion.  The effect of 
lipoproteins on T cells has mainly been explored in relation to atherosclerosis and 
cardiovascular disease.  LDL has been demonstrated to play a role in Th17-dependent 
inflammation in atherosclerosis.48–52  HDL, conversely, appears to promote a Treg-
dependent reduction in inflammation.51,53  Clinically, the acute phase response of 
inflammation affects cholesterol levels by increasing serum triglycerides and decreasing 
HDL levels.126–129  Systemic inflammation has also been shown to decrease serum LDL, 
although enteric inflammation caused by celiac disease, H. pylori, Vibrio cholera and 
derangements in the microbiome in psoriatic arthritis, appears to cause the opposite 
response.130–137  
Together, these observations suggest that the serum lipid balance between 
available FA and the complex lipoproteins LDL and HDL may play a direct role in the 
choice between the anti-inflammatory Treg and pro-inflammatory Tcon phenotype. 
Thereby, the lipid balance is capable of priming the immune system towards 
exaggerated inflammation or autoimmunity.  We hypothesized that genetic 
dysmorphisms in, or blockade of, mitochondrial FA oxidation would lead to impaired 
Treg proliferation and conversely inhibition of high rate glycolysis would cause the 
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reverse.  Furthermore, we expected that supplementation of complex lipoproteins in the 
form of LDL would cause a pro-inflammatory IL-17-predominant response, while 
supplementation with HDL would affect proliferation of suppressive Tregs. 
 
IV.2 Materials and Methods 
Mice 
 BALB/cByJ (BALB/c) mice, which express a deficiency in short-chain acyl-CoA 
dehydrogenase (SCAD) needed for FA b-oxidation, and C57BL/6J (B6) mice used as 
controls, 3-6 months of age, were purchased from The Jackson Laboratory (stock 
#001026) and maintained at the Baylor Scott & White/Texas A&M animal facility, 
Temple, TX.138  All animal studies were reviewed and approved by the Institutional 
Animal Care and Use Committee. 
 
Cell Isolation and Medium 
 Splenocytes were isolated from 3-4 pooled spleens using a 40 µm nylon strainer.  
Red cells were lysed using either Gey’s or ACK lysing buffer (ThermoFisher 
Scientific).139 Cells were washed twice in phosphate buffered saline and suspended in 
RPMI 1640 medium (Gibco) supplemented with 5% fetal bovine serum for plating at 
concentrations of 0.5 – 1.0 x 106 live cells/mL.   
 
Metabolic Reagents 
 Etomoxir (Sigma Aldrich), a malonyl-CoA analog that blocks carnitine palmitoyl 
transferase in FA oxidation, was used at doses of up to 100 mM.140 2-deoxyglucose 
(2DG) (Sigma Aldrich), an inhibitor of high rate glycolysis, was used at a 4 mM 
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concentration.141,142  Purified human plasma LDL and HDL (>95% SDS-PAGE) were 
purchased from Lee Biosciences and used at concentrations of up to 500 mg/dL to 
mimic levels measured in serum.  
 
T Cell Activation 
 To mimic T cell receptor (TCR) recognition of antigen and MHC and co-
stimulation, the requirements for T cell activation, cells were activated with 1 µg/mL of 
purified anti-CD3e antibody (clone 145.2C11, eBioscience) and 1 µg/mL purified anti-
CD28 antibody (eBioscience) at 37° for 0-48h as specified. 
 
Flow Cytometry Analysis for Surface and Intracellular Markers 
 Eight-color flow cytometry was performed using the BD FacsCanto II instrument 
and Flow Jo software (TreeStar). The following antibodies were used: rat anti-mouse 
FITC-CD4, PE-Cy7-CD8a, APC-CD25, PE-Cy7-CD25, PacBlu-CD4 (BioLegend), PE-
FoxP3, PerCP Cy5.5-FoxP3, APC-IL-17 (eBioscience), and APC-Cy7-CD3e (BD). Cells 
were permeabilized using an anti-mouse/rat FoxP3 staining set (eBioscience) for 
intracellular staining of IL-17 or Foxp3 when indicated.  Mitochondrial membrane 
potential (MMP) was measured using MitoTracker Red (ThermoFisher Scientific).  
 
Statistical Analysis 
 Parametric tests, including Student’s t test for two comparisons and two-way 
analysis of variance (ANOVA) with Dunnett’s for multiple comparisons, were used to 
calculate differences between means.  Chi square was used to calculate differences in 
  42 
frequencies in pooled data between control and treatment groups using Prism 7.0d 
(GraphPad Software). Statistical significance was set at p <0.05.  
 
IV.3 Results 
 
Strain-specific Genetic Differences in Metabolism affect Treg Proliferation upon Antigen 
Encounter 
To investigate how genetic differences in lipid metabolism affect the T cell 
response to antigen, we performed experiments comparing B6 and BALB/c 
splenocytes, due to previously described genetic differences in b-oxidation in the 
BALB/c mouse.138  BALB/c splenocytes had significantly higher CD8+ and CD4+T 
lymphocyte frequencies prior to TCR activation. TCR stimulation resulted in a four-fold 
increase in Treg numbers, which persisted through 48 hours (Figure 9).  Without 
stimulation, Tregs were close to undetectable by 48 hours. Concurrent measurement of 
MMP showed a higher proportion of MMPhigh cells, supporting a heavier dependence on 
glycolysis. On the other hand, though B6 splenocytes had lower frequencies of all T 
cells, a 20-fold increase in Tregs was observed at 24 hours with TCR activation. By 48 
hours, however, Treg numbers had decreased to a similar proportion as BALB/c (four-
fold increase from baseline).  
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Figure 9. Analysis of CD4+ lymphocytes, CD4+ Tregs and CD8+ T cells after TCR activation. A. Representative 
flow cytometry for B6 and BALB/c at 24h. B. Frequencies of CD4+ T cells and Tregs at 24 and 48h. C. 
Mitochondrial membrane potential (MMP) of splenocytes after TCR activation with Mito+ population representing 
high MMP.  All analyses showed statistically significant difference using Chi square at p<0.05. 
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Strain-specific Responses to Metabolic Inhibitors on Tregs  
  We then explored the separate effects of blocking glycolysis and lipid oxidation 
on Treg frequency (Figure 10).  Treatment with 2-DG to block glycolysis led to 
decreased activation of Tregs in both strains, with a greater response seen in BALB/c 
mice.  Inhibition of FA oxidation by etomoxir initially led to a decrease in Treg activation 
in B6 mice but conversely an increase in Treg activation in BALB/c mice.  After 48 
hours, both groups showed increased Treg activation with a higher response seen in 
the BALB/c mice.  Both groups showed higher populations of MMPlow cells with 2-DG 
treatment, supporting increased lipid utilization. However, though blocking FA oxidation 
with etomoxir led to the reverse in the C57BL/6, it did not affect MMP in the BALB/c 
mice. Additionally, T cell activation in glucose-free and lipid-free media with isolated FA 
supplementation led to complete loss of T cells, suggesting that FA alone cannot be 
sufficiently metabolized for growth and survival.  Both oxidative and glycolytic machinery 
are necessary in tandem. 
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Figure 10.  Treatment of B6 and BALB/c splenocytes with 2-DG. A. Activation index was calculated by 
normalizing Treg numbers to the control group; B. Treatment of B6 and BALB/c splenocytes with 
etomoxir; C. Baseline MMP of CD4+ T cells; D. MMP of TCR-activated CD4+ T cells. Statistical 
significance was set at p<0.05. 
 
Lipids Complexed into LDL and HDL affect Treg and IL-17+ T Cell Frequency 
Since the above experiments showed that genetic differences in lipid metabolism 
appeared to affect the response to T cell activation, we next aimed to determine 
whether changes in lipid availability – specifically complex lipoproteins in the form of 
LDL and HDL – would have a direct effect in vitro on lymphocytes without TCR 
stimulation.  Analysis of the effect of increasing doses of LDL and HDL on Treg and IL-
17+ cell proliferation on B6 splenocytes showed that there was not a significant dose-
dependent effect of LDL on Treg or IL-17+ cell frequency (p=0.49 and p=0.06, 
respectively).  Tregs did show a significant linear decrease in LDL-supplemented 
medium as a function of time (p<0.0001). There was a significant time-dependent 
increase in IL-17+ cells in LDL-supplemented and HDL-supplemented media, especially 
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at 12 hours (p<0.0001).  Meanwhile, HDL was found to have both a significant time- and 
dose-dependent effect on Treg frequency (p=0.03 and p=0.01, respectively), though an 
unexpected attenuation of Treg numbers was observed (Figure 11).   
 
Differences in T Cell Activation due to Lipoproteins 
Finally, we sought to show that, upon antigen encounter, differences would be 
observed in Treg and IL-17+ cell proliferation, dependent on lipid availability. We found 
that LDL exposure was associated with a decrease in Treg and an increase in IL-17+ 
proliferation at 12h and 24h (p<0.0001) but, again, a relationship to increasing dose was 
not observed compared to control.  However, HDL again showed a time- and dose-
dependent decrease in Tregs (p<0.0001 and p=0.02, respectively) but also in IL-17+ 
cells (p=0.01 and p=0.02, respectively) (Figure 12). The effect on Tregs appeared to 
diminish once an extremely high dose of HDL (500 mg/dL) was utilized. 
 
 
 
 
 
    
  47 
 
 
Figure 11.  Effect of lipoproteins on Tregs and IL-17+ cells.  Pooled B6 splenocytes were cultured at 37° 
in triplicate in increasing levels of lipid.  A. Representative flow cytometric analysis for Tregs and IL-17+ 
cells.  B.  Treg and IL-17+ cell proliferation in response to differing concentration of LDL at 12 and 24h.  
C.  Treg and IL-17+ cell proliferation in response to differing concentration of HDL at 12 and 24h.  * 
depicts statistically significant difference on time-dependent change at p<0.05. 
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Figure 12. Effect of lipoproteins on TCR-activated Tregs and IL-17+ cells.  Pooled B6 splenocytes were 
cultured at 37°C in triplicate in increasing levels of lipid and activated with anti-CD3e and anti-CD28. A.  
Treg and IL-17+ cell proliferation in response to differing concentration of LDL at 12 and 24h.  B.  Treg 
and IL-17+ cell proliferation in response to differing concentration of HDL at 12 and 24h.   
 
IV.4 Summary 
Lipid availability and metabolism have been shown to be profoundly important in 
enteric, autoimmune, and vascular disease.  This implies that underlying derangements 
in lipid metabolism may be correlated with increased autoimmunity or predisposition to 
exaggerated inflammatory responses.  The present study was designed to explore 
whether strain-specific differences in lipid oxidation lead to observable differences in the 
T cell/Treg compartment of adaptive immunity.   
We showed that BALB/c mice, demonstrated to have upregulated glycolysis via 
higher proportions of MMPhigh cells, had both increases in baseline CD8+ and CD4+ T 
  49 
cells as well as exaggerated responses of overall CD4+ T cells, including Tregs, when 
antigenic TCR activation was mimicked. Without stimulation, Treg levels diminished to 
insignificant levels, despite continued high numbers of overall CD4+ cells. This suggests 
that TCR activation is necessary in the BALB/c mice for sustaining circulating Tregs due 
to its decreased ability to utilize short chain fatty acids, leading to an overall 
inflammatory CD4+ T cell phenotype.  Meanwhile, though the B6 mice had significantly 
lower absolute numbers of CD8+ and CD4+ T cells, Treg proportions were higher and 
increased relatively more in comparison when antigen exposure occurred.  Therefore, 
with intact lipid oxidation machinery, the B6 mice had a more anti-inflammatory 
phenotype and an ability to mount a significantly higher suppressive response to turn off 
the inflammatory cascade earlier than the BALB/c mice.  
BALB/c mice had a greater decrease in Tregs in response to inhibition of 
glycolysis with 2DG that was unaffected by a blockade of carnitine palmitoyl 
transferase, further supporting the idea that the BALB/c mouse is dependent on 
glycolysis and mounting of a pro-inflammatory response for Treg proliferation.  While 
much of the susceptibility of the BALB/c mouse to diverse autoimmune diseases, 
including autoimmune encephalitis, systemic lupus erythematosus, myocarditis and 
arthritis, has largely been attributed to differences in MHC alleles (I-Ad I-Ed) compared to 
B6 alleles (I-Ab), our study therefore also implicates this defect in lipid utilization in the 
susceptibility.143–146  
Our next step was to address whether, in the absence of metabolic 
abnormalities, lipoprotein availability can be manipulated to improve Treg frequency or 
decrease IL-17+ production.  This has implications for diseases linked to Treg 
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derangements, as simple dietary manipulation or targeted initiation of lipid-lowering 
agents may improve disease outcome.  In clinical studies, statins, HMG-CoA reductase 
inhibitors that decrease LDL and increase HDL, have been shown to attenuate colitis as 
well as improve autoimmune diseases such as inflammatory bowel disease and multiple 
sclerosis.126,147,148  We found that LDL did not appear to have a direct effect on CD4+ or 
Treg numbers.  Additionally, HDL decreased both Tregs and IL-17. 
Multiple mechanisms may explain our findings.  We showed that both oxidative 
phosphorylation and glycolysis are required for T cell proliferation, and rapidly dividing 
cells may have metabolized available excess lipoproteins for energy without direct toxic 
effects.  HDL may have preferentially attenuated proliferation of inflammatory CD4+ 
subsets, rather than increasing Treg numbers.  In parallel to previous observations in 
clinical acute phase responses, TCR activation may have decreased available HDL 
levels as well, preventing a positive effect on the infrequent Tregs, or preferentially used 
pro-inflammatory HDL subsets.149  Finally, our findings may also mean that instead of a 
direct effect on T cells, lipoproteins exert their effect through the professional antigen 
presenting cells (APCs).  In fact, B cells have recently been shown to have high levels 
of LDL receptors and affect T cell responses differentially based on lipid availability and 
costimulatory molecules.49,56,150 
Thus, the major limitation of our study is that the use of in vitro assays prevents 
modeling of the complex anatomic, cellular and cytokine milieu of the lymphatic system.  
Additionally, lipoprotein metabolism is coordinated in the liver, through which the 
majority of dietary lipids are trafficked for delivery or excretion and likely have high direct 
interaction with immune cells.  This microenvironment cannot be modeled in a Petri 
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dish.  Though our studies implicate the importance of genetic differences in lipid-
directed immunity and show a correlation between T cell activation and lipoprotein 
availability, more studies are needed to further explore these relationships. 
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V. LIPIDS AFFECT IMMUNE PROFILES THROUGH CLIP+B CELL AND 
GAMMA DELTA T CELL INTERACTIONS IN THE LIVER 
 
V.1 Introduction 
In the classical teachings of immunology, the focus has been on two arms of the 
immune system: innate immunity, which includes neutrophils and macrophages that are 
immediate responders to an inflammatory insult, and adaptive acquired immunity, in 
which antigen-specific B- and T- lymphocytes are the most well-characterized. 
Professional APCs, including B cells, macrophages, and dendritic cells, function as the 
intermediaries between these two arms of immunity.  APCs engulf and process protein 
antigens into peptides in the lysosome that are then presented on the cell surface 
complexed with MHC class II (MHCII) molecules.  CD4+ T cells, or helper T cells, in turn 
recognize these antigenic peptides through their TCR, made of a heterodimer of an 
alpha and beta chain (ab T cells), to effect activation through the production of 
cytokines that either assist in the humoral B cell response or that assist in activation of 
the CD8+ T cell, cytotoxic T cell, responses.151,152  
T cell activation therefore requires recognition of antigen presented in the context 
of MHC.  However, this alone is not sufficient for a response.  Co-stimulation, mediated 
by ligand-receptor interactions between APC and T cell, is necessary as a second 
signal.153,154  The most well-studied co-stimulatory molecules are the B7 molecules on 
APCs (B7-1/CD80 and B7-2/CD86) that interact on T cells with CD28 to activate or 
CTLA-4 to downregulate the T cell response.155–162 
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However, closer examination of B- and T-cells has shown subsets of 
lymphocytes that do not follow this paradigm.  B cells that carry invariant chain-derived 
(CD74) class II-associated invariant chain peptides (CLIP), rather than antigen 
complexed with MHC II, are activated by innate immune signals.  CLIP+ B cells serve at 
the interface of innate and adaptive immunity by promoting inflammatory responses 
without antigenic stimulation and may play a significant role in the chronic inflammation 
of autoimmune disease.163–166  T cells that carry the gd-TCR, gamma delta T cells 
(GDTC), are usually CD4-/CD8+, but can also be CD4+ or double negative, do not 
necessarily require peptide presentation in MHC and can recognize lipid antigens.167–172  
Many of the GDTC produce the inflammatory cytokine IL-17 and develop in thymus-
independent viscera, such as the gut, as intraepithelial lymphocytes (IELs).17,55,84,120,172–
178 
The liver functions as the main effector organ in the processing of dietary lipids 
throughout life, as well as a primary lymphoid organ prenatally.  Fats are either burned 
for energy or processed and packaged by hepatocytes into VLDL for delivery of FA and 
cholesterol for cellular use in the peripheral tissues. HDLs then return cholesterol from 
peripheral tissues to the liver for disposal through bile (Figure 13).  
Recently, LDL has been demonstrated to play a role in pro-inflammatory IL-17-
dependent inflammation in atherosclerosis.48–52 Conversely, HDL appears to promote 
an anti-inflammatory Treg-dependent reduction in inflammation.51,53  Independently, 
infection with rhesus rotavirus, a major intestinal pathogen that also induces 
experimental biliary atresia in mouse models, has been shown to induce IL-17 
production and concomitant decrease in IL-10 by intrahepatic T cells with no significant 
  54 
similar effect seen in mesenteric lymph nodes or gut mucosa.55 B cells have been 
shown to have a high density of LDL receptors and the ability to internalize LDL for 
processing in the lysosome, where antigen association with MHC II occurs as well 
(Figure 13).56  Cholesterol content has also recently been linked to differential regulation 
of GDTC activation.179 
 
 
 
 
Figure 13. Circulation of lipids as mediated through the liver 
 
The study outlined in our preceding chapter aimed to show a direct effect of LDL 
and HDL on the Treg/Th17 axis.  We found that strain-specific deficiencies in lipid 
processing indeed affected Treg dynamics.  HDL level correlated with both Treg and IL-
17+ cell frequency.  From this, we hypothesized that CLIP+ B cells and GDTC as the 
main source of IL-17 are the mediators of the lipid-dependent inflammatory responses 
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that lead to attenuation in Treg numbers.51–53,126,127,129,130,133,135,137,148,180,181  In this 
chapter, we aimed to determine if lipid processing in the liver is the key to directing the 
body towards enteral tolerance or autoimmunity/inflammation via differential expression 
of co-stimulatory molecules on CLIP+ B cells and/or activation of GDTCs. 
 
V.2 Materials and Methods 
Mice 
C57BL/6J (B6) mice, 3-6 months of age, were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA) and maintained at the Baylor Scott&White/Texas 
A&M animal facility, Temple, TX.138  All animal studies were reviewed and approved by 
the Institutional Animal Care and Use Committee. 
 
Cell Isolation and Purification 
Splenocytes and hepatocytes were isolated from B6 mice and single cell 
suspensions made using a 40 µm nylon strainer.  Discontinuous 40%/70% Percoll 
density gradient centrifugation was used for leukocyte enrichment. 
  
Cell Culture 
Spleens were pooled (3-4 per group) for adequate cell numbers of splenocytes 
and cultured in 96-well plates.  RPMI 1640 medium (Gibco) supplemented with 5% fetal 
bovine serum was used for plating cells in triplicate at concentrations of 1.0 x 106 live 
cells/mL.  Cells were incubated at 37° for up to 30h.  
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Reagents 
Purified human plasma LDL and HDL (>95% SDS-PAGE) were purchased from 
Lee Biosciences and used at concentrations of up to 200 mg/dL to mimic serum levels 
in humans. Recombinant human Fas:Fc (Enzo Life Sciences) was used at a 
concentration of 0.75 µg/mL. The rhFas:Fc binds to Fas ligand (FasL) on T cells, 
including GDTC, B cells, natural killer (NK) cells and some innate immune cells and 
inhibits soluble FasL-mediated lysis of cells sensitive to Fas-induced cell death.  The 
rhFas:Fc can also block FasL-dependent cell proliferation.182  Cells were  incubated in 
lipoproteins for 6h to allow acclimation prior to treatment for 12h (18h group) and 24h 
(30h group) with reagents. 
 
T Cell Activation 
To mimic TCR stimulation and co-stimulation by antigen, cells were activated 
with 1 µg/mL of purified anti-CD3e antibody (eBioscience) and 1 µg/mL purified anti-
CD28 antibody (eBioscience) at 37° for up to 30h as specified. 
 
Flow Cytometry Analysis for Surface and Intracellular Markers 
Eight-color flow cytometry was performed using the BD FacsCanto II instrument 
(BD Biosciences) and FlowJo software (TreeStar).  FACS staining was performed 
according to standard protocols. The following antibodies were used: rat anti-mouse 
PacBlu-CD4, PE-Cy7-CD25, PacBlu-CD19 (BioLegend), APC-GD TCR, PE-B71, PE-
Cy5-B71, APC-B72, PE-Cy5-MHC II (eBioscience), PacBlu-B220, APC-Cy7-CD3e 
(BD), and FITC-CLIP (Santa Cruz). Per group, 10000 events were collected and 
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visualized according to forward (cell size) and side scatter (cellular granularity). Isotype 
controls were used for populations of interest. 
 
Statistical Analysis 
Parametric tests, including Student’s t test with Holm-Sidak correction for multiple 
comparisons, were used to calculate differences between means.  Linear regression 
and Pearson r correlation was used to show dose-dependent relationships of absolute 
cells numbers and percentages of cells. Prism 7.0d was used for all analyses 
(GraphPad Software). Statistical significance was set at p <0.05.  
 
V.3 Results 
Preferential Dose-dependent Increases in T cell Subsets in Response to HDL and LDL 
Supplementation 
In vitro, we observed a dose-dependent increase in Treg frequency and in the 
percentage of Tregs from total cells in response to HDL, with no similar effect seen with 
LDL supplementation.  This dose-response appeared to occur at concentrations greater 
than 50 mg/dL, the clinically defined target for serum HDL levels.  This suggests that 
Tregs can utilize HDL but not LDL, a finding we have observed in our previous studies.  
This may also suggest that availability of HDL allows naïve CD4+ T cells to differentiate 
preferentially into Tregs over effector conventional T cells (Figure 14C, 14D). 
Meanwhile, the opposite effect was seen with GDTCs, with a significant dose-
dependent increase in both absolute frequency and proportion seen in response to LDL 
(Figure 14C).  HDL appeared to also cause an increase in absolute GDTC frequency, 
but when the proportion of overall T cells was analyzed, this effect vanished (Figure 
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14D).  These observations lead us to believe that GDTCs may proliferate in response to 
LDL availability, either via primary utilization of LDL as an energy source as a 
consequence of FA oxidation or recogntion of LDL particles associated with MHCII as a 
lipid antigen or lipidated peptide.     
 
LDL Decreases Number of CLIP+ B Cells 
Our next set of experiments was conducted to explore the relationship of 
lipoprotein levels and B cells.  We found that HDL did not affect the total number of 
CLIP+B cells.  However, LDL appeared to cause a decrease in CLIP+B cell numbers 
(Figure 15B).  This is consistent with previous observations that B cells have a high 
density of LDL receptors.56 LDL is endocytosed into lysosomes by B cells, the 
compartment where the peptidic antigens can displace CLIP in the groove of MHCII to 
enable antigen presentation.  It has been described that exogenous lipid availability 
changes acidity of the lysosome and surface expression of MHCII.183  We reasoned that 
components released from LDL digestion, either FA, cholesterol or proteins, likely 
interacted with, or even replaced, CLIP in the binding groove of MHCII to cause the 
observed decrease in CLIPhigh B cells, priming the immune system to target lipidated 
antigen possibly via recognition by GDTCs. 
  We then explored whether treatment with rhFas:Fc would reverse the observed 
loss of CLIP+B cells or improve Treg proliferation by blocking lipoprotein-induced Fas-
mediated killing of either population. Use of rhFas:Fc to block FasL-mediated cell death 
by GDTCs has been described previously.184  Increased GDTCs in response to LDL 
was inversely correlated with Treg and CLIP+B cell frequency (Figures 14C, 14D, 15B).  
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Figure 14. Effect of LDL and HDL on GDTCs and Tregs. A. Representative flow cytometric analysis of 
1x104 cells analyzed after culture with increasing concentrations of LDL and HDL for 18h.  T cells defined 
as CD3+B220- cells, GDTCs defined as CD3+CD4-GDTCR+ cells, Tregs defined as 
CD3+CD4+CD25high cells. B. CD3+B220+ cells were found to be 100% GDTCR positive in all 
populations, with a direct increase in expression of both markers observed. C. Linear regression of 
frequency of Tregs and GDTCs for dose-response effect of exposure to increasing concentrations of LDL 
and HDL for 18 hours, p<0.05 for difference between slopes for both datasets.  D.  Pearson r correlation 
for dose-response effect on Treg and GDTC percentage of total T cells. * denotes statistically significant 
correlation set at p<0.05.  
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This may have resulted from the inhibition of Fas-dependent proliferation of CLIP+B 
cells.  In the absence of lipid, there was actually a significant decrease in CLIP+B cells 
when treated with rhFas:Fc, and any addition of lipid negated this effect (Figure 15C).  
However, rhFas:Fc treatment improved Treg proliferation at low doses of HDL and 
decreased Tregs at low doses of LDL, suggesting that lipid-primed GDTCs may reduce 
Tregs, though this did not reach statistical significance (Figure 15E). 
Additionally, we observed that CLIP+ B cells were largely CD80+CD86+high cells, 
as determined by flow cytometry, which has not previously been described in the 
literature (Figure 15C).  As a final step, this led us to examine the expression of the B7 
co-stimulatory molecules to determine whether these molecules may also play a role in 
differential immune responses to lipid. 
 
Co-stimulatory Molecules CD80 and CD86 on B Cells are Differentially Affected by Lipid 
 Further in vitro studies showed that exposure of B cells to LDL for 30h led to 
increases in CD80+ (B71) B cells in a dose-responsive manner, but no significant 
decrease in CD86+ (B72) cells.  Meanwhile, HDL led to significantly decreased 
numbers of B71, B72 cells, double positive, and total B cells at high doses (200mg/dL), 
though the effect on B71 cells first became significant at a lower dose (100mg/dL) 
(Figure 16B).  B72 cell frequency ran parallel to total B cell frequency, in comparison to 
other subsets, suggesting that at baseline B72 is constitutively expressed on B cells and 
an external signal is required for expression of B71, which serves to stimulate a 
stronger inflammatory response.  This further implies that increased expression of the 
co-stimulatory molecule B71 in response to LDL and decreased expression secondary 
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to HDL exposure may be a key point at which divergence to an inflammatory or 
tolerizing state occurs, respectively. 
 
 
Figure 15. Effect of LDL and HDL on CLIP+ B cells. A. Representative flow cytometric analysis of 1x104 
cells analyzed after culture with increasing concentrations of LDL and HDL for 18h. B cells defined as 
CD3-CD19+ cells, CLIP+B cells defined as MHCIIhigh CLIP+ cells from B cell gate.  B. Linear regression of 
CLIP+B cell frequency in response to increasing doses of LDL and HDL showed a significant decrease 
with LDL but no relationship to HDL.  C. Treatment with Fas:Fc showed significant decrease of CLIP+B 
cells without lipoproteins, which disappeared with lipoprotein treatment.  D. CLIP+B cells were found to be 
almost exclusively CD80+highCD86+high.  E. Fas:Fc treatment improved Treg proliferation at low doses of 
HDL but decreased Treg proliferation at low doses of LDL. Multiple Student’s t-test with Holm-Sidak 
correction for multiple comparisons used to detect differences between means. * denotes statistically 
significance defined as p<0.05. 
 
 
We also wanted to determine whether the immune changes fostered by 
lipoprotein availability were mediated by differential MHCII expression.  By measuring 
the MFI of MHCII staining on B cells to indicate MHCII expression, we found no effect in 
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response to differing doses or types of lipoproteins (Figure 16C). Interestingly, we 
observed that each subset of B cells (CLIP+, B71, B72 and double positives) appeared 
to have a unique MHCII expression fingerprint that was unchanged by lipoprotein 
availability, with CLIP+ cells having the highest and B71 having the lowest MHCII levels 
per cell.  This may suggest that co-stimulatory molecules also direct MHCII expression, 
a finding that warrants further investigation.   
 
Hepatic B Cell Populations Differ from Spleen Populations in Mice 
Because the liver is the central organ for lipid metabolism, we theorized that 
lymphocyte populations found in the liver might reflect a role in promoting enteral 
tolerance to dietary fats.  Our previous observations supported LDL-induced decreases 
in CLIP+ B cells and increases in GDTCs.  In fact, we found similar proportions in the 
liver compared to spleen of B6 mice.  Significantly lower numbers of B cells and CLIP+ 
B cells were found in the liver compared to spleen, though the overall proportion of B 
cells that were CLIP+ was higher in the liver (Figure 17A).  Conversely, liver had more T 
cells, including CD4+ and GDTCs, but fewer Tregs, which trended towards significance 
(Figure 17B).  Hepatic GDTC:Treg ratio (defined as the inflammatory index – Figure 
17C) favored GDTCs, while a statistically significant reversal was seen in the spleen.  
Overall, these observations suggest that the key mediators of enteral tolerance to lipid 
propagated by the liver are GDTCs, promoted by its lipid-rich microenvironment.   
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Figure 16. Effect of LDL and HDL on B cell co-stimulatory molecules and MHCII expression. A. 
Representative flow cytometric analysis of 1x104 cells analyzed after culture in increasing concentrations 
of LDL and HDL for 30h.  B cells defined as CD3-CD19+ cells, B71/CD80+ cells defined from B cell gate 
as CD80+CD86-, B72/CD86+ cells defined as CD80-CD86+ and double positive population identified as 
CD80+CD86+. B. Comparison of proliferation of CD80+, CD86+ and double positive cells in response to 
LDL and HDL. C. Geometric mean fluorescence intensity (MFI) of MHCII expression evaluated by flow 
cytometry for B cell subsets and in response to LDL and HDL treatment. * denotes statistically 
significance defined as p<0.05. 
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Figure 17.  Frequency of lymphocyte populations and subsets in spleen and liver. A. B cells in spleen and 
liver (n=6-12 per group).  B.  T cells in spleen and liver. C. Inflammatory index of lymphocytes - defined as 
ratio of GDTCs to Tregs. Student’s t test used to compare differences between means. * denotes 
statistically significance defined as p<0.05. 
 
 
V.4 Summary 
Overall, our data shows the importance of lipoprotein particles on immune 
profiles.  First, we were able to demonstrate that LDL is important in the proliferation of 
GDTCs.  We also found that LDL caused decreases in CLIP expression on B cells.  
Together, this suggested that CLIP was replaced by lipid particles on B cells for 
presentation to GDTCs.  GDTCs in the gut are largely pro-inflammatory IL-17-producing 
cells.173,174  IL-17 GDTCs in the liver in response to pathogen have also been shown to 
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promote IL-17-induced inflammation or promote PE during pregnancy.55,185  However, 
tolerizing roles to acute infection in other anatomic compartments, including a protective 
effect against LPS-induced lung injury have been described as well.186  Furthermore, 
GDTCs in the form of IELs have been shown to be critical for maintenance of gut 
epithelial integrity.17,175 This, along with our previous data, suggests that in low LDL 
environments, GDTCs may promote tolerance to lipid, but in states of excess lipid can 
promote IL-17-based inflammation.173,179  Furthermore, improved HDL levels may 
ameliorate this effect, based on their ability to increase Tregs to suppress an 
inflammatory response. 
The preponderance of CLIP+B cells and GDTCs in the liver compared to spleen 
suggests that this critical balance may occur in the liver as an anatomic compartment.  
We hypothesized that lipid processing in the liver is key to directing the body towards 
enteral tolerance or autoimmunity/inflammation via differential expression of co-
stimulatory molecules on CLIP+ B cells and/or activation of GDTCs.  In fact, if excess 
LDL particles begin to displace CLIP in MHCII in B cells and are then presented as 
antigen to GDTCs, this may be the crucial step in effecting a pathologic response both 
in the gut through the enterohepatic circulation or systemically via the vena cava to the 
cardiac circulation.  The direct effect seen in CD80 expression suggests that this 
response may occur in tandem, with CD80 expression increasing only after a pro-
inflammatory state has become predominant.  If these changes can be demonstrated in 
the peripheral blood as well, CD80 detection may even be used as a diagnostic target in 
disease states where the response to enteral lipid is found to be of importance, such as 
inflammatory bowel diseases, celiac disease, or even necrotizing enterocolitis.17,187  
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Because the liver functions as the anatomic juncture between the enteric circulation and 
the systemic circulation, these findings may have important implications, not just for 
enteric tolerance, but even systemic autoimmune disease and transplant rejection. 
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VI. FORMULA FEEDING PREDISPOSES INFANTS WITH ABERRANT 
LIPID METABOLISM TO NECROTIZING ENTEROCOLITIS 
 
VI.1 Introduction 
NEC is a disease of newborns that results in epithelial destruction of the 
gastrointestinal tract leading to a cascade of local and systemic effects.  The incidence 
is 1 in 1000 live births with a mortality of 15 - 30% and it is almost exclusively a disease 
of premature and low birth weight infants.1–4  Formula feeding has been shown in 
multiple multi-system clinical studies to significantly increase the incidence of NEC 
compared to breast-feeding, especially in these high-risk populations.188–191  However, 
an incomplete understanding of the underlying pathogenesis of the disease has led to 
minimal improvements in mortality over the last few decades.11 
The current paradigm is that an initial breach of the intestinal epithelial barrier 
leads to a pro-inflammatory immune response and the inability of the premature 
immune system to then counteract the inflammatory cascade leads to downstream 
effects which manifest as NEC (Figure 1).  A dysregulation in the ability to mount 
antigen-specific tolerance to the microbiome and to enteric antigens has been shown to 
be key.  Secretory IgA, required for oral and microbiome tolerance, is reduced in 
preterm infants.  In experimental colitis models, decreased exposure to IgA leads to a 
more pro-inflammatory gut microbiota and intestinal epithelial gene expression 
associated with inflammatory bowel disease.18    
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T lymphocyte subsets are crucially important in NEC, as well.  Tregs, CD4+ T 
lymphocytes that promote self-tolerance, are attenuated in the gut epithelium of infants 
who develop NEC.19  Pro-inflammatory cytokine expression, especially of IL-6 that 
disposes T cells to differentiate towards the pro-inflammatory T-cell subsets (including 
CD4+ Th17 cells), is also proportionately increased during development of NEC.20 IELs, 
resident lymphocytes of the gut mucosa that usually express the ϒδ T-cell receptor 
(GDTCs) and unlike classical T cells do not mount a peptide antigen-specific response, 
are necessary during development for self-tolerance and habituation to commensal 
microbiota.16  Infants with NEC have been shown to have a reduction in this subset of 
innate-like lymphocytes, as well.17   
In previous chapters, we have shown the importance of lipid environment on 
imbalances in the Treg/IL-17+ and GDTC axis.  This takes on special significance in the 
neonate, who switches from obtaining nutrients by placental transfer in utero to oral 
ingestion of nutrition after birth.  Breast milk is a complex biofluid of which lipids are the 
largest source of energy, contributing 40-55% of its composition.41  Lipids are packaged 
into a specialized carrier molecule called the MFG.  The MFG is composed of a TAG 
core surrounded by a unique triple membrane structure called the MFG membrane.43,44 
Infant formula does not contain MFG and tends to have vegetable source-derived lipids 
which differ greatly in size and composition.44,45  Supplementation of formula with MFG 
appears to protect against Clostridium dificile-induced gut inflammation in neonatal rat 
models and against gut barrier disruption and inflammation in systemic LPS 
infection.46,47 
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We have also previously shown that strain-specific genetic differences in lipid 
metabolism machinery in mice lead to distinctive T cell profiles.  Lipid metabolism is a 
complex process that initiates in the gut and is regulated in a developmental and tissue-
specific manner (Figure 18).  The liver plays a key role in mediating this process.  
Dietary lipids, mostly TAGs, are processed and packaged by the intestinal epithelium 
into chylomicron particles conjugated to apolipoprotein B48 (apoB48) for delivery to the 
liver.  Hepatocytes produce VLDLs conjugated to apolipoprotein B100 (apoB100) for 
delivery to the periphery. LDLs of increasing density all contain one molecule of 
apoB100, which is the major ligand recognized by LDL receptors in extrahepatic tissues 
for cholesterol uptake.192  ApoB48 is the truncated form of apoB100, encoded by a 
single gene on human chromosome 2 and generated as a result of apoB mRNA editing 
enzyme (encoded by APOBEC), which is developmentally regulated in the small 
intestine during fetal development.193–195 ApoB deficiency has been shown to 
predispose to severe invasive Staphylococcus aureus infection.196  Meanwhile, deletion 
of microsomal triglyceride transfer protein (MTTP), which assists in assembly of 
lipoproteins in both liver and intestine, improved mortality and intestinal injury during 
exposure to pathogen.197 
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We propose a two-hit model of NEC, in which formula feeding serves as the first 
insult in infants with aberrations in lipid metabolism genes, priming the immune system 
towards creating a repository of pro-inflammatory GDTCs via presentation of lipid 
antigens by CLIP+ B cells.  Exposure to an enteric pathogen causing a breach of the 
intestinal epithelium serves as the second insult, leading to an exuberant inflammatory 
response ultimately manifesting as NEC.     
 
VI.2 Materials and Methods 
NCBI GEO Database 
 Differential whole genome microarray analysis had been previously performed on 
intestinal tissues collected for non-inflammatory intestinal conditions (n=4) compared to 
those of infants with NEC (n=5) using a human Gene 1.0 ST array system (Affymetrix 
Inc.) and was publicly available for accession through the NCBI GEO datasets, GEO 
accession number GSE46619.198  Four datasets from the GEO series were retrieved in 
addition to the top 250 differentially expressed genes and data preprocessing carried 
out using R.  A t-test was used to decide which genes were differentially expressed for 
Figure 18. Lipid metabolism mediated by the liver 
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each dataset.  The four datasets included HLA genes that encode MHC proteins 
needed for antigen presentation, and genes that regulate polyunsaturated fatty acid 
metabolism (PUFA), including CYP450 genes that encode metabolic enzymes, FADS 
genes that encode fatty acid desaturases and genes encoding apolipoproteins needed 
for lipid metabolism. The GEO2R bioinformatics tool provided by NCBI was used for 
graphical representation. 
 
Mice 
C57BL/6J (B6) mice were purchased from The Jackson Laboratory (Bar Harbor, 
ME, USA) and maintained at the Baylor Scott & White/Texas A&M animal facility, 
Temple, TX.  All animal studies were reviewed and approved by the Institutional Animal 
Care and Use Committee.  5-day-old mice were separated from dams and gavage-fed 
75 – 100 µL of Esbilac formula or Esbilac formula + 1.5% DSS every 3 hours for 5 days 
and sacrificed at day of life (DOL) 10.  Thymus, liver and spleen were isolated for further 
analysis. 
 
Reagents 
DSS is a heparin-like polysaccharide that is used to cause destruction of the 
gastrointestinal epithelium in bowel disease models.35  A 1:1 combination of DSS of 
molecular weights 5 kD and 40 kD was used to induce pan-intestinal epithelial 
injury.199,200     
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Cell Isolation 
Spleens and livers were removed and single cell suspensions made using a 40 
µm nylon strainer.  Discontinuous 40%/70% Percoll density gradient centrifugation was 
used for leukocyte enrichment for flow cytometry. 2-3 spleens and livers were pooled for 
10-day-old mice for adequate cell yield.  
 
Flow Cytometry Analysis for Surface and Intracellular Markers 
Eight-color flow cytometric analysis was performed on fresh thymus and spleen 
cells using the BD FacsCanto II instrument (BD Biosciences) and FlowJo software 
(TreeStar).  FACS staining was performed according to standard protocols. The 
following fluorochrome-conjugated antibodies were used: rat anti-mouse PacBlu-CD4, 
PE-Cy7-CD25, PacBlu-CD19, PE-CCR9, hamster anti-mouse FITC-Helios (BioLegend), 
rat anti-mouse PE-CD3e, PE-Cy5-MHC II, PerCP Cy5.5-FoxP3, hamster anti-mouse 
APC-GD TCR (eBioscience), rat anti-mouse PacBlu-B220, APC-Cy7-CD3e, hamster 
anti-mouse FITC-GD TCR, (BD Pharmingen), and rat anti-mouse FITC-CLIP (Santa 
Cruz).  Isotype controls were used to define negative gating for populations of interest. 
 
Immunofluorescence 
 Livers from dam-fed, formula-fed and DSS-fed neonatal mice were isolated and 
fixed in 4% paraformaldehyde followed by ethanol.  Antigen-retrieval was conducted in 
a citrate buffer, followed by sucrose protection prior to freezing.  Slides were made of 7-
µm cryosections stained with DAPI nuclear counterstain (Southern BioTech) and 
incubated with fluorochrome-conjugated antibodies FITC-GDTCR and PE-CD3, as 
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detailed above.  An Olympus BX51 fluorescent microscope was used for detection of 
fluorescent staining using 10X magnification and DAPI (excitation: 320-390 nm, 
emission: 430 -490 nm), FITC (excitation: 455 – 500 nm, emission: 570-560 nm) and 
TRITC (excitation: 505-560 nm, emission: 575-655 nm) filters. 
 
Statistical Analysis 
Parametric tests including Student’s t test and ANOVA were used to calculate 
differences between means.  Prism 7.0d was used for all analyses (GraphPad 
Software). Statistical significance was set at p <0.05.  
 
VI.3 Results 
Downregulation of Lipid Metabolism Genes in NEC-affected Intestine 
We first evaluated differential gene expression by microarray analysis of intestine 
collected for non-inflammatory bowel conditions (controls) and NEC.201  We had 
expected to find both immunogenetic differences and metabolic differences, but no 
differences in the expression of HLA genes or in CYP450 and FADS genes were found 
between the two groups.  However, significantly decreased expression of genes critical 
for cholesterol metabolism and lipoprotein assembly were found in the NEC babies, 
including various apolipoproteins such as APOA4, which encodes apolipoprotein A-IV (p 
= 0.00002), APOB that encodes apolipoprotein B (p=0.00003), and APOC3 that 
encodes apolipoprotein C-III (p=0.003) (Figure 19A).  Differences were also found in 
genes encoding factors and enzymes required for lipoprotein assembly and transport 
(Figure 19B).  APOBEC, which encodes the apolipoprotein B mRNA editing enzyme 
  74 
(p=0.012) needed for post-translational modification of ApoB100 to ApoB48, as well as 
APOBEC1 complementation factor were both decreased in NEC infants. We also found 
significantly decreased expression of Mttp, necessary for the secretion of apoB-
containing lipoproteins.202    
 
Infant Liver Contains Higher Treg and GDTC Populations than Adult Liver 
 Because the liver is the central organ for lipid processing and packaging, we then 
turned our attention to describing the differences in hepatic lymphocyte populations 
between adult and exclusively dam-fed neonatal mice, to determine age-dependent 
differences. We used comparison to spleen as a control within age-groups.  B cell 
populations were significantly higher in both liver and spleen of neonates compared to 
adults as well as higher in neonatal liver compared to spleen.  Meanwhile, frequency of 
CLIP+ B cells was identical in both organs in neonates and when compared to adults.   
However, given the total B cell numbers observed, this additionally suggested a much 
lower actual proportion of CLIP+ B cells in the neonate than in the adult (Figure 20A). 
 Analysis of T lymphocyte populations, on the other hand, showed no significant 
differences in total T cells.  The key differences were found in the exploration of the 
various subsets of interest.  We observed that neonatal liver and spleen both had half 
the number of CD4+ T cells of the adult, though this did not reach statistical significance 
in the liver. Neonatal liver also had significantly higher numbers of Tregs and natural 
Tregs (nTregs), a subpopulation of Tregs defined by expression of the Ikaros 
transcription factor, Helios, that develop intrathymically and not in response to foreign 
antigen, when compared to neonatal spleen as well as to adult liver.203  Because of the 
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role of the liver as a primary lymphoid organ in fetal life, this finding likely reflects the 
need for tolerance to both self and maternal peptide during embryological development.   
 
 
 
Figure 19. Differential gene expression of genes governing lipid metabolism.  Blue column shows control 
(n=4) and red column shows NEC (n=5) specimens. Statistical significance set at p<0.05 
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Figure 20. Lymphocyte frequency and subsets in adult and neonatal liver and spleen.  A. A significantly 
higher B cell frequency was found in neonatal liver and spleen compared to adults with no significant 
difference found in CLIP+B cell frequency, suggesting much lower proportion in neonatal liver and spleen. 
B. Similar T cell numbers found in all tissues in adult and neonate.  Neonatal liver was found to have 
higher levels of Tregs, nTregs and GDTCs than neonatal spleen and adult liver. C. GDTC:Treg ratio in 
favor of GDTCs in all tissues except adult spleen.  * denotes statistical significance between same tissue 
in adult v. neonate.  # denotes statistical significance between spleen and liver in same group. Statistical 
significance set at p<0.05 for comparisons of means using Student’s t test. 
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 Finally, we also found a notable increase in GDTC frequency in neonatal liver 
compared to adult with a significant decrease in neonatal compared to adult spleen.  
Because the cytokine-expression profile of these GDTCs was not evaluated, we do not 
know if they are the inflammatory IL-17-producting GDTC or a tolerizing subpopulation.  
The ratio of GDTC to Treg in all organs and age groups favored a GDTC-predominant 
profile except in adult spleen, though these differences appeared more marked in the 
neonate.  Given the accompanying proportions of lower CD4+ and higher Tregs, we 
anticipate that GDTCs found in the neonatal liver of dam-fed babies are likely a 
tolerizing subset that proliferate prior to encountering food or enteric pathogens. 
Because animals were not caged in a germ-free facility, this may also reflect a response 
to the microbiome inherited from the mother.  
 
 
Lymphocytes in Liver Show Marked Increase of Gut-homing Chemokine Receptor 
CCR9 
 Next, we explored the possibility that the T cells found in the liver expressed 
markers that directed their interaction with enteric antigens.  T-cell homing is regulated 
by specific chemokine receptor expression and the chemokine receptor CCR9 (CD199) 
has been shown to be a marker for homing to the small intestine.204,205  CCR9 has also 
been shown to be important specifically in GDTC migration and/or development in the 
intestine, with CCR9 KO animals showing lower frequencies of GDTCs in the small 
intestine.206,207  
 We examined the expression of CCR9 by fluorescence staining of adult splenic 
and hepatic T lymphocytes to determine first if there were tissue-specific differences in 
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intraabdominal viscera.  All T cells subsets from the liver had observably increased 
levels of CCR9 expression, while CCR9 levels in splenocytes were essentially 
undetectable (Figure 21A&C).  This suggests that larger proportions of T cells in the 
liver are intended for interaction with enteric antigen.  Interestingly, CD8+ and CD4+ 
cells expressed CCR9 more frequently in the adult compared to GDTCs, in contrast to 
our expected result.  We interpreted this to highlight the difference in effector T cells that 
had encountered enteric pathogenic peptides (CD8+ and CD4+) versus nutritional lipids 
(GDTC), with the expectation that adults had encountered both higher loads of 
pathogenic flora as well as a more nutritionally complex diet with advancing age.    
We then compared neonatal liver to the adult in order to further examine this 
theory (Figure 21A-C).  Neonatal liver and spleen both had observably higher 
populations of CCR9+ GDTCs than adult liver, though this was not statistically 
significant in the liver.  Again, this suggested to us a separate subpopulation of GDTCs 
necessary for neonatal development found in dam-fed infants, rather than inflammatory 
IL-17+GDTCs promoted by high lipid concentrations.173,179 
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Figure 21. Flow cytometric analysis of T cell populations in adult and neonatal liver and spleen.  A.  
Representative gating analysis of adult is shown in liver and spleen. Upper panel: Cells were first 
characterization by forward (cell size) and side scatter (nuclear granularity).  Doublets were excluded.  
Staining for CD3 and CD4 was then visualized to isolate CD8+ T cells (CD3+CD4-), CD4+ T cells 
(CD3+CD4+) and GDTCs (CD3highCD4-).  Lower panel: nTregs were gated from the CD4+ cells by 
identifying FoxP3highHelioshigh cells. CCR9 staining was then identified by comparison to isotype controls 
in CD8+, CD4+ and GDTCs, respectively.  Numbers shown were frequencies of parent gate.  B.  Similar 
flow cytometry analysis was conducted in pooled neonatal liver and spleen (3 organs per group).  C.  
CCR9 expression on T cell subsets in adult and neonatal liver and spleen. * denotes statistical 
significance between same tissue in adult v. neonate.  # denotes statistical significance between spleen 
and liver in same group. Statistical significance set at p<0.05 for comparisons of means using Student’s t 
test.  
 
 
 
Formula Feeding Increases CLIP+B Cells and GDTCs in Spleen 
 Finally, we wanted to show the in vivo effect on lymphocytes in response to 
formula-feeding, as the anatomic microenvironment was felt to be crucial to this 
process.  We examined the spleens of 10-day-old neonatal mice which had been either 
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dam-fed (n=4) or formula-fed (n=8) (Figure 22A and B, respectively).  Dam-fed mice 
showed low numbers of both B and T cells in comparison to formula-fed mice.  T-cells 
populations were comprised of much lower percentages of GDTCs and B cell 
population of lower percentages of CLIP+ cells.  Formula-fed mice had six times more T 
cells, of which there was a three-fold increase in GDTCs. Formula feeding also led to a 
doubling of B cell frequency with a 10-fold increase in CLIP+B cells.  Comparison of 
these groups also showed a separate population of B220+CD3+ cells, which has not 
previously been described in the literature but were predominantly GDTCR+.  When we 
examined the livers of these two groups with immunofluorescence staining, there 
appeared to be more CD3+ T cells in the formula-fed livers, but equal numbers of 
GDTCs (Figure 22D top and middle panels). 
 Our last step was to determine how an insult to the intestinal epithelium, as is 
assumed to occur in NEC, affected these lymphocyte profiles.  We found a doubling of 
GDTCs detectable in spleen compared to formula-fed controls and a 25-fold increase of 
in the B220+ GDT cell population.  In contrast, CD3+ T cells and GDTCs became 
undetectable in the liver.  Additionally, the population of splenic CLIP+B cells was 
reduced by half when compared to formula-fed infants.   
Together, we interpreted these findings to mean that formula-feeding led to 
amplified lymphocyte populations, especially GDTCs and CLIP+B cells, which 
proliferate in the spleen.  Higher numbers of hepatic GDTCs were not observed in 
response to formula-feeding.  This leads us to believe that a subset of naïve GDTC 
proliferate and migrate from the spleen to the liver (including B220+GDTCs), which 
functions as the repository of gut-homing GDTCs that react in response to 
  81 
environmental cues from nutritional or infectious factors.  Upon breach of the intestinal 
epithelium, CLIP+B cells from the spleen and gut-homing GDTCs from the liver then 
migrate to intestine to effect an inflammatory immune response. 
 
VI.4 Summary 
Our exploration of differential gene expression of the tissues of actual babies 
affected by NEC first substantiated the need for further research into this area.  
Decreased apoB expression and editing may cause an altered ability of both the liver 
and intestine to utilize and transport lipids in complex lipoproteins, causing an 
overabundance of lipid in the microenvironment of the cell populations critical to this 
disease.  Aberrant fat digestion through the enterohepatic circulation has been shown to 
have a direct toxic impact on the small intestine.208  Previous groups have demonstrated 
an increase in CD4+ and CD8+ T cells in LDL receptor knockout mice in response to 
high-fat diets.48  We had previously been able to demonstrate that lipoprotein availability 
and character directly affect immune cell populations and that high LDL levels correlate 
with a pro-inflammatory immune phenotype via IL-17 and/or GD T cells.  This study then 
shows that lipid metabolism is crucial to the development of NEC, a finding that has not 
been described previously.      
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Figure 22. Flow cytometry of pooled spleens of neonatal mice.  A. Dam-fed x 10 days (n=4). T cells 
identified as CD3+B220- cells and B cells as CD3-B220+. T cell gate then analyzed for GDTCR staining 
compared to isotype control; B cells identified as CD3-B220+ and gated for CLIP and MHCII to identify 
CLIP+B cells.  B. Formula-fed from DOL 5-10 (n=8) or C. Formula-fed and treated with 1.5%DSS from 
DOL 5-10 (n=8).  Numbers shown are percent of parent gate.  Statistical analysis was not conducted due 
to pooling of tissue for adequate cell yield. D. Immunofluorescence staining of liver sections for nuclear 
counterstain with DAPI (first column), PE-CD3 to identify T-cells (2nd column) and FITC-GDTCR to identify 
GDTCs (3rd column). 
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Our previous studies demonstrated that LDL leads to increased IL-17+ cells and 
GDTCs and decreased CLIP+B cells, while HDL promotes Treg proliferation. We were 
able to further characterize and implicate this inverse relationship of GDTCs and 
CLIP+B cells in vivo in response to formula-feeding, suggesting this leads to priming of 
the immune system towards inflammation/autoreactivity and poor enteral tolerance.   
We also observed much greater B cell and Treg/GDTC populations in neonatal 
liver compared to the adult.  This is consistent with the very recent finding in humans 
that fetal liver is critical to lymphopoiesis of lipid-derived tolerizing B cells, which may 
persist through adult life.209  The function of the observed GDTCs in our study is not 
known, but we expect the B220+GDTCs that we have first described here to parallel the 
ontogeny and function of the tolerizing B cells, in the absence of lipid aberrations or 
other factors that push them towards autoreactivity and inflammation. 
The implications of lipid metabolism in the development of NEC are novel but, we 
believe, also significant.  Further studies are needed to delineate the influence of lipid 
metabolism on its pathology.  Aberrant lipid metabolism or lipoprotein assembly and 
delivery may even correlate with many of the long-term phenomena observed in the 
babies who suffer NEC, including the disproportionate incidence of IUGR, intestinal 
failure-associated liver disease, and even neurodevelopmental disability.210–213  If our 
data are further substantiated, these observations will signal the need for a paradigm 
shift in the treatment of neonatal NEC.   
In the future, cholesterol metabolism genes may be utilized for diagnostic 
purposes to identify babies at highest risk for development of this disease.  Because 
lipid-lowering therapies via statins, changing of lipid formulations in baby formula or 
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entirely depending on banked breast milk for nutrition are relatively easy therapies, 
earlier intervention with these agents in identified babies may finally improve the 
morbidity and mortality of this life-altering disease. 
  85 
VII. SUMMARY AND CONCLUSIONS 
 
VII.1 Summary 
 In vitro, we showed that complex lipoproteins LDL and HDL had direct effects on 
directing the phenotype of T lymphocytes.  HDL had an overall anti-inflammatory effect 
in our studies, as increasing HDL appeared to decrease frequency of IL-17-producing T 
cells but expand the Treg proportion of CD4+ T cells.  Conversely, LDL was shown to 
increase the GDTC subset of the T cell compartment without having a significant effect 
on Treg numbers.   We then explored whether this effect was due to the B cell acting as 
professional antigen presenting cell intermediary.  In the case of the HDL-Treg dynamic, 
no such relationship was observed.  However, LDL supplementation caused an 
increase in expression of co-stimulatory molecule CD80 (B71) while at the same time a 
decrease in CLIP expression.  This suggested that LDL likely displaced CLIP in MHCII 
causing co-expression of CD80, an interaction which led to the observed proliferation of 
GDTC. 
 Because the liver is the central organ for processing of dietary lipids into 
lipoproteins, we then aimed to characterize the differences in hepatic lymphocyte 
populations.  We hypothesized that the liver, well-known to be tolerogenic in hepatic 
transplant patients, would have a much higher proportion of Tregs than spleen.  
Interestingly, we found the converse, with a high proportion of CLIP+ B cells and GDTC 
in adult murine liver.  Furthermore, neonatal liver had an even greater subset of hepatic 
GDTC.  Additionally, GDTC of neonatal liver showed a high expression of the gut-
homing molecule CCR9.  Together, we believe this signifies a differing role for liver-
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specific GDTC that is tolerogenic rather than the classic inflammatory IL-17-producing 
GDTC found in the gut.   
 Next, our experiments using different strains of mice and mouse models 
endeavored to show how these effects of lipids and complex lipoproteins on immune 
cells were significant at an organismal level.  Lymphocytes from BALB/c mice with 
defects in beta oxidation were found to have a preferential decrease in both baseline 
Treg number and Treg proliferation in response to antigen.  This suggested that 
dysfunctional lipid metabolism would attenuate tolerance to antigen.  To explore this in 
vivo,  we isolated liver and spleen in our neonatal mouse model of formula-feeding and 
intestinal epithelial damage using DSS.  Here, we found that formula-feeding led to 
increased CLIP+B cells and GDTC in spleen compared to breast milk feeding.  Breach 
of intestinal epithelium led to an exaggerated proliferation of GDTC, especially B220+ 
GDTC, but a decrease in splenic CLIP+B cells.  Meanwhile, formula feeding did not 
change hepatic GDTC numbers, though DSS supplementation led to a complete 
absence of detectable GDTC in the liver.   
 Our clinical data from human babies recapitulates the importance of these 
findings and points us to the next stage in these studies.  We showed that babies with 
IUGR born to mothers with PE had a nine-fold higher risk of NEC than IUGR babies 
born to non-PE mothers.  Examination of cord blood in babies with IUGR showed 
decreased frequencies of normally functioning Tregs, while non-IUGR pre-term babies 
were found to have high frequencies of less functional Tregs compared to term normal-
sized controls.  Additionally, dyslipidemia in PE has previously been linked to fetal beta 
oxidation defects, though this has never been linked to NEC.  Using public microarray 
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data, we found that babies who suffered from surgical NEC had decreased expression 
of genes necessary at multiple stages of lipoprotein assembly and delivery, including 
APOB (transcription of apoB-B), APOBEC1 (post-translational modification of apo-B100 
to apo-B48), and MTTP (secretion of apoB-B containing lipoproteins).  Together, this 
hints that intact lipid metabolism is crucial for tolerance, and derangements may thus 
lead to amplified severity of inflammatory conditions such as NEC, especially in the 
context of an underdeveloped or primed immune system as seen in premature formula-
fed infants. 
 
VII.2 Conclusions 
Despite being one of the most highly investigated disease processes in pediatric 
research, the morbidity and mortality of NEC has remained largely unchanged over the 
last several decades.  The fact that it almost exclusively affects premature and IUGR 
babies who are fed formula rather than breast milk is well-known by even the most 
junior trainee in both pediatrics and surgery.  Yet, this widespread awareness and vast 
body of research has as yet resulted in no satisfactory methods to either pre-emptively 
pinpoint those babies who will develop NEC or prevent the progression of low-grade 
medically manageable NEC to severe surgical disease characterized by transmural 
necrosis or even perforation.  Approximately 20% of NICU costs, totaling about $5 
billion annually, continue to be due to NEC, with babies who require surgery spending 
upwards of three months in the NICU after birth.214  Of the 70% who survive surgical 
NEC, long-term problems including neurodevelopment delays, short-gut syndrome, 
lifetime total parenteral nutrition, hepatic failure or even need for bowel transplant 
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prevent achieving a normal childhood and acceptable quality of life.  Thus, the next 
steps in this investigation should be to translate our findings into either preventive, 
diagnostic or therapeutic  tools. 
Two pathways emerge from our studies that may be used for diagnostic 
purposes.  The first and more obvious one is to screen neonates for lipid metabolism 
abnormalities, especially those that we have previously described as significant in 
surgical NEC.  Further studies on a population level are needed to determine which 
derangements are associated with NEC and whether they have predictive value of 
disease severity.  The other option is to quantify either CD80 or GDTC in peripheral 
blood of formula-fed infants as a predictor of intolerance.  This may be less fruitful, 
however, due to the nonspecific nature of inflammatory markers in general, but may 
have promise as a screening tool to identify babies at risk. 
If population-based studies indeed show a significant causative relationship of 
aberrant lipid metabolism in the development of NEC, this also points to a role for early-
initiation of lipid-lowering therapies in at-risk populations.  While breast milk remains the 
ideal option, perhaps in those babies whose only nutritional option is formula, 
cholesterol binding agents such as ezetimibe may decrease incidence or severity of 
NEC.  Additionally, this suggests a re-formulation of the lipid component of 
commercially available baby formula may be needed, potentially through restructuring of 
lipids to more closely resemble MFG. 
Finally, our studies found a novel population of GDTC that proliferated in 
response to intestinal mucosal damage.  Further exploration is needed as to the nature 
of these lymphocytes as GDTCs remain an enigmatic population.  However, if, as our 
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studies suggest, GDTC are the culprits in the inflammatory manifestations of NEC, this 
opens up multiple avenues for therapeutic strategies.  Previous studies in mouse 
models suggest a role for adoptive transfer of Tregs in ameliorating intestinal 
inflammation, which our findings loosely support.  However, other strategies such as 
GDTC depletion therapies or displacement of lipid antigen from MHCII to prevent 
antigen recognition by GDTCs may prove even more useful to turn off the specific 
immune response that leads to necrosis and perforation.  Though there still remain 
many more questions than answers in this seemingly incurable disease, we believe our 
data lay the groundwork for a novel interpretation of this disease and finally point to the 
promise for a cure.
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